地址:武汉市洪山区光谷大道35号光谷总部国际时代 二期1栋1301
电话:15172431432
传真:18995651644
邮箱:sales@amyjet.com

艾美捷科技代理美国Ran Biotechnologies公司全系列表面活性剂产品。
NEAT FLUOROSURFACTANTS
Neat (un-dissolved) 008-FluoroSurfactant
1g (cat#: 008-FluoroSurfactant-1G)
5g (cat#: 008-FluoroSurfactant-5G)
10g (cat#: 008-FluoroSurfactant-10G)
50g (cat#: 008-FluoroSurfactant-50G)
100g (cat#: 008-FluoroSurfactant-100G)
0.5kg (cat#: 008-FluoroSurfactant-500G)
1kg (cat#: 008-FluoroSurfactant-1000G)
FLUOROSURFACTANTS IN SOLUTIONS
008-FluoroSurfactant dissolved in common fluorinated oils (e.g. HFE7500, FC40)
Sample size, choice of oil and surfactant concentration vary, depending on customer requests. Most commonly, solutions are supplied as 2 weight % or 5 weight % either in HFE7500 or FC40:
50g of 2 weight % 008-FluoroSurfactant in HFE7500 (cat#: 008-FluoroSurfactant-2wtH-50G)
50g of 2 weight % 008-FluoroSurfactant in FC40 (cat#: 008-FluoroSurfactant-2wtF-50G)
500g of 2 weight % 008-FluoroSurfactant in HFE7500 (cat#: 008-FluoroSurfactant-2wtH-500G)
500g of 2 weight % 008-FluoroSurfactant in FC40 (cat#: 008-FluoroSurfactant-2wtF-500G)
20g of 5 weight % 008-FluoroSurfactant in HFE7500 (cat#: 008-FluoroSurfactant-5wtH-20G)
20g of 5 weight % 008-FluoroSurfactant in FC40 (cat#: 008-FluoroSurfactant-5wtF-20G)
200g of 5 weight % 008-FluoroSurfactant in HFE7500 (cat#: 008-FluoroSurfactant-5wtH-200G)
200g of 5 weight % 008-FluoroSurfactant in FC40 (cat#: 008-FluoroSurfactant-5wtF-200G)
FLUOROSURFACTANT KITS
“FS-Kit#1” contains:
10g of 5 weight % 008-FluoroSurfactant in HFE7500
10g of 5 weight % 008-FluoroSurfactant in FC40
50g of neat HFE7500
50g of neat FC40
“FS-Kit#2” contains:
1g neat 008-FluoroSurfactant
60g of neat HFE7500
60g of neat FC40
“NoChipDrop-Kit1” contains:
Emulsion Oil – 500microL
Aqueous Recovery Oil – 125microL
Gel Bead Slurry – 350microL
“NoChipDrop-Kit2” contains:
Emulsion Oil – 2.2mL
Aqueous Recovery Oil – 0.55mL
Gel Bead Slurry – 1.4mL
Fluorinated surfactants containing:
Fluorescein (cat# FluoreFS)
Rhodamine (cat# FS-Rhodamine)
Biotin (cat# FS-Biotin)
BenzylGuanine (cat# FS-BG)
Sugar (cat# FS-Sug)
< " data-original="http://genvivo.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="艾美捷科技代理Ran Biotechnologies全系列产品"> 艾美捷科技代理Ran Biotechnologies全系列产品
SurModics公司成立于1979年,拥有30多年的临床诊断、生物医药、科研产品研发和开发经验,是体外诊断技术的领先品牌。可提供多种产品,主要包括蛋白稳定剂、封闭剂、缓冲剂、比色底物及化学发光底物、和抗原、抗体等。
Surmodics is the global leader in surface modification technologies for vascular medical devices and a leading provider of chemical components for in vitro diagnostic (IVD) tests and microarrays. Following two acquisitions of Creagh Medical and NorMedix – recognized innovators in balloon catheters and delivery systems – we have combined capabilities in proprietary surface technologies, as well as device design, development and manufacturing that enable us to significantly increase the value we offer our medical device customers. We are focused on developing highly differentiated, total vascular device solutions to the most demanding clinical challenges. The company’s R&D pipeline is rich with novel innovations within the field of vascular medicine. Even as we expand our capabilities, our mission remains to improve the detection and treatment of disease.
Surmodics公司主要产品:
(1)蛋白稳定剂/封闭剂
免疫检测稳定剂(微量滴定板、乳胶小珠、磁珠);微阵列芯片稳定剂; 封闭剂;结合物稳定剂(AP,HRP);无BSA稳定剂;稳定剂包:包含免疫检测稳定剂、结合物稳定剂、无BSA稳定剂、可选择稳定剂各25ml。
(2)BioFX底物/终止剂
比色HRP底物、比色AP底物、化学发光HRP底物、化学发光AP底物、TMB底物、ABTS和pNPP底物。
(3)稀释液/缓冲液/IHC试剂/附属试剂
SurModics提供ELISA稀释液、清洗液、免疫组化试剂。
(4)DIARECT自身免疫和免疫疾病抗原
DIARECT自勉和免疫疾病抗原的质量和敏感性都经过校验。主要包括:ANCN相关疾病、自勉型肝炎和肝脏疾病、肾炎综合症、甲状腺自勉疾病、血栓栓塞综合症、莱姆病、肠炎、胃肠腹腔疾病、细小病毒等。
(5)BioFX抗体和链酶亲和素
SurModics IVD为免疫印迹、免疫组化、ELISpot、RIA、微阵列应用提供十种不同物种和六种宿主二抗。
(6)微阵列芯片
微阵列芯片通过共价键链接RNA、DNA和蛋白,使用方便,兼容性好,适用于大部分阵列和扫描设备。
<更多详情请联系
艾美捷科技有限公司
全国服务热线:400-6800-868
邮箱:sales@amyjet.com
网站:www.amyjet.com
" data-original="http://genvivo.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="Surmodics"> Surmodics
Chemicell公司位于德国柏林,该公司主要进行创新的以纳米级磁珠为基础的生物分离、基因转染&检测系统开发和生产工作。开发的重点在于设计以客户为导向特别兼容了实验室自动化的即用型试剂盒。
chemicell develops and produces innovative bioseparation- gene transfection and detection systems based on magnetic nano- and microparticles. Focus of our product development is to design high quality customer-oriented "ready-to use" kits with special orientation towards the compatibility for labor automatisation. It is chemicell's policy to be open for cooperations with other companies or scientific institutes to maximize the chances and opportunities that evolve from the rapid development of biotechnological procedures and to distribute innovative new products.
主要产品包括:
Magnetofection™
Biomagnetic Separation
Magnetic Microparticles
Magnetic-Fluorescent Microparticles
Magnetic Nanoparticles
Magnetic-Fluorescent Nanoparticles
Microspheres-Non-Magnetic
Silica Microspheres-Non-Magnetic
Silica Fluorescent Microspheres-Non-Magnetic
Magnetic Separators
DNA / RNA Purification
PEG derivates
" data-original="http://genvivo.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="Chemicell"> Chemicell
<| 产品名称 | 货号 | 化学式 | 分子量 | CAS# |
| 2,5-Anhydro-6-azido-6-deoxy-1,3-O-isopropylidene-D-glucitol | S20031 | C9H15N3O4 | 229,23 | N/A |
| 4-Azido-4-deoxy-1,6:2,3-dianhydro-β-D-mannopyranose | S97085 | C7H9N3O2 | 167,17 | N/A |
| Methyl-3,6-anhydro-7-azido-2,7-dideoxy-4,5-O-isopropylidene-D-alloheptonate | S10191 | C11H17H3O5 | 271,27 | N/A |
| 1,4-Anhydro-3-azido-2-O-benzoyl-3-deoxy-D-xylitol | S10192 | C12H13N3O4 | 263,25 | N/A |
| 1,4-Anhydro-2-azido-3-O-benzoyl-2-deoxy-D-arabitol | S10189 | C12H13N3O4 | 263,25 | N/A |
| 2-Azido-2-deoxy-1,4;3,6-dianhydro-D-glucitol | S03293 | C6H9N3O3 | 171,15 | N/A |
| 6-Azido-6-deoxy-1,2,3,4-tetra-O-acetyl-α,β-D-galactopyranose | S05174 | C14H19N3O9 | 373,32 | N/A |
| 6-Azido-6-deoxy-1,2,3,4-tetra-O-acetyl-α,β-L-galactopyranose | S02174 | C14H19N3O9 | 373,32 | N/A |
| DIBMA free acid | D-20054 | N/A | N/A | N/A |
| DIBMA monosodium salt | D-20055 | N/A | N/A | N/A |
| Glyco-DIBMA | D-20056 | N/A | N/A | N/A |
| n-Octyl α-D-glucopyranoside (aOG) > 99% highly purified | D97011 | C14H28O6 | 292,38 | 29781-80-4 |
| Methyl 6-O-(-n-heptylcarbamoyl)-α-D-glucopyranoside (HECAMEG) | D20034 | C15H29NO7 | 335,4 | 115457-83-5 |
| n-Hexyl β-D-glucopyranoside > 99% highly purified | D99014 | C12H24O6 | 264,4 | 59080-45-4 |
| n-Heptyl β-D-glucopyranoside (HeptG) > 99% highly purified | D07033 | C13H26O6 | 278,4 | 78617-12-6 |
| n-Octyl β-D-glucopyranoside (OG) > 99% highly purified | D97001 | C14H28O6 | 292,38 | 29836-26-8 |
| n-Octyl β-D-glucopyranoside (OG-C) > 99,5% for crystallography | D97001-C | C14H28O6 | 292,38 | 29836-26-8 |
| n-Nonyl β-D-glucopyranoside (NG) > 99% highly purified | D99011 | C15H30O6 | 306,40 | 69984-73-2 |
| n-Nonyl β-D-glucopyranoside (NG-C) > 99,5% for crystallography | D99011-C | C15H30O6 | 306,40 | 69984-73-2 |
| n-Decyl β-D-glucopyranoside (DG) > 99% highly purified | D99006 | C16H32O6 | 320,43 | 58846-77-8 |
| n-Undecyl β-D-glucopyranoside (UDG) > 99% highly purified | D11023 | C17H34O6 | 334,4 | 70005-86-6 |
| n-Dodecyl β-D-glucopyranoside (DDG) > 99% highly purified | D99007 | C18H36O6 | 348,5 | 59122-55-3 |
| 4-trans-(4-trans-Propylcyclohexyl)-cyclohexyl α-maltoside > 99% (t-PCCαM) | D99019-C | C27H47O11 | 547,67 | N/A |
| n-Dodecyl α-maltoside (αDDM) > 99% highly purified | D99020 | C24H46O11 | 510,63 | 116183-64-3 |
| n-Hexyl β-maltoside (HexM) > 99% highly purified | D20018 | C18H34O11 | 426,4 | 870287-95-9 |
| n-Heptyl β-maltoside (HeptM) > 99% highly purified | D14001 | C19H36O11 | 440,48 | N/A |
| n-Octyl β-maltoside (OM) > 99% highly purified | D20020 | C20H38O11 | 454,4 | 82494-08-4 |
| n-Nonyl β-maltoside (NM) > 99% highly purified | D20015 | C21H40O11 | 468,41 | 106402-05-5 |
| n-Nonyl β-maltoside (NM-C) > 99,5% for crystallography | D20015-C | C21H40O11 | 468,41 | 106402-05-5 |
| n-Decyl β-maltoside (DM) > 99% highly purified | D99003 | C22H42O11 | 482,6 | 82494-09-5 |
| n-Decyl β-maltoside (DM-C) > 99,5% for crystallography | D99003-C | C22H42O11 | 482,6 | 82494-09-5 |
| n-Undecyl β-maltoside (UDM) > 99% highly purified | D99012 | C23H44O11 | 496,6 | 253678-67-0 |
| n-Undecyl β-maltoside (UDM-C) > 99,5% for crystallography | D99012-C | C23H44O11 | 496,6 | 253678-67-0 |
| n-Dodecyl β-maltoside (DDM-C) > 99,5% for crystallography | D97002-C | C24H46O11 | 510,63 | 69227-93-6 |
| n-Tridecyl β-maltoside (TDM) > 99% | D20016 | C25H48O11 | 524,6 | 93911-12-7 |
| n-Tridecyl β-maltoside (TDM-C) > 99,5% for crystallography | D20016-C | C25H48O11 | 524,6 | 93911-12-7 |
| n-Tetradecyl β-maltoside (TeDM-C) > 99,5% for crystallography | D20028-C | C26H50O11 | 538,6 | 18449-82-6 |
| n-Pentadecyl β-maltoside (PDM-C) > 99,5% for crystallography | D20040-C | C27H52O11 | 552,35 | N/A |
| n-Hexadecyl β-maltoside (HeDM) > 99,5% | D20029-C | C28H54O11 | 566,72 | 98064-96-1 |
| n-Dodecyl β-maltoside (DDM) > 99% highly purified | D97002 | C24H46O11 | 510,63 | 69227-93-6 |
| Isopropyl 1-thio-β-D-galactopyranoside (IPTG) | S02122 | C9H18O5 | 238,30 | 367-93-1 |
| n-Heptyl 1-thio-β-D-glucopyranoside (HTG) > 99% highly purified | D99013 | C13H26O5S | 294,4 | 85618-20-8 |
| n-Octyl 1-thio-β-D-glucopyranoside (OTG) > 99% highly purified | D20014 | C14H28O5S | 308,44 | 85618-21-9 |
| n-Nonyl 1-thio-β-D-glucopyranoside (NTG-C) > 99,5% highly purified | D14038-C | C15H30O5S | 322,4 | 98854-15-0 |
| n-Decyl 1-thio-β-D-glucopyranoside (DTG) > 99% highly purified | D20021 | C16H32O5S | 336,4 | 98854-16-1 |
| n-Dodecyl 1-thio-β-maltoside (DDTM-C) > 99,5% highly purified | D20022-C | C24H46O10S | 526,6 | 148565-58-6 |
| n-Heptyl 1-thio-β-D-glucopyranoside (HTG-C) > 99,5% highly purified | D99013-C | C13H26O5S | 294,4 | 85618-20-8 |
| n-Octyl 1-thio-β-D-glucopyranoside (OTG-C) > 99,5% highly purified | D20014-C | C14H28O5S | 308,44 | 85618-21-9 |
| MEGA-8 (N-Octanoyl-N-methylglucamin) | D98004 | C15H31NO6 | 321,4 | 85316-98-9 |
| MEGA-9 (N-Nonanoyl-N-methylglucamin) | D99005 | C16H33NO6 | 335,4 | 85261-19-4 |
| MEGA-10 (N-Decanoyl-N-methylglucamin) | D99008 | C16H33NO6 | 335,4 | 85261-19-4 |
| 1-O-(n-Octyl)-tetraethyleneglycol (C8E4) | D20038 | C16H34O5 | 306,44 | 19327-39-0 |
| 1-O-(n-Decyl)-hexaethyleneglycol (C10E6) | D20041 | C22H46O7 | 422,60 | 5168-89-8 |
| 1-O-(n-Decyl)-nonaethyleneglycol (C10E9) | D20033 | C28H58O10 | 554,75 | 26183-52-81 |
| 1-O-(n-Dodecyl)-tetraethyleneglycol (C12E4) | D20035 | C20H42O5 | 362,54 | 5274-68-0 |
| 1-O-(n-Dodecyl)-octaethyleneglycol (C12E8) | D20039 | C28H58O9 | 538,75 | 3055-98-9 |
| 1-O-(n-Dodecyl)-nonaethyleneglycol (C12E9) | D20032 | C30H62O10 | 582,81 | 3055-99-0 |
| 1-O-(n-Dodecyl)-decaethyleneglycol (C12E10) | D20031 | C32H66O11 | 626,86 | 6540-99-4 |
| 1-O-(n-Tridecyl)-octaethyleneglycol (C13E8) | D20030 | C29H60O9 | 552,78 | 9043-30-5 |
| N,N-Dimethyl-n-dodecylamine-N-oxide (LDAO) | D71111 | C14H31NO | 229,4 | 1643-20-5 |
| Sucrose monolaurate (SUMOL) | S98001 | C24H44NO12 | 524,6 | 25339-99-5 |
| Monoolein (1-O-Oleoyl-rac-glycerol) | D20036 | C21H40O4 | 356,5 | 111-03-5 |
| 3-[(3-Cholamidopropyl)-dimethylammonio]-1-propane sulfonate | D99009 | C32H58N2O7S | 614,89 | 75621-03-3 |
| 3-[(3-Cholamidopropyl)-dimethylammonio]-2-hydroxy-1-propane sulfonate | D99010 | C32H58N2O8S | 630,87 | 82473-24-3 |
| n-Nonyl-phosphocholine (C9-PC) Purity > 99% | S10197 | C14H32NO4P | 309,38 | 253678-64-7 |
| n-Decyl-phosphocholine (C10-PC) Purity > 99% | S10195 | C15H34NO4P | 323,41 | 70504-28-8 |
| n-Undecyl-phosphocholine (C11-PC) Purity > 99% | S10196 | C16H36NO4P | 337,4 | 253678-65-8 |
| n-Dodecyl-phosphocholine (C12-PC) Purity > 99% | S10190 | C17H38NO4P | 351,46 | 29557-51-5 |
| n-Tridecyl-phosphocholine (C13-PC) Purity > 99% | S10198 | C18H40NO4P | 365,49 | 85775-42-4 |
| n-Tetradecyl-phosphocholine (C14-PC) Purity > 99% | S10194 | C19H42NO4P | 379,51 | 77733-28-9 |
| n-Pentadecyl-phosphocholine (C15-PC) Purity > 99% | S10199 | C20H44NO4P | 393,54 | 146801-07-2 |
| n-Hexadecyl-phosphocholine (C16-PC) Purity > 99% | S01241 | C21H46NO4P | 407,57 | 58066-85-6 |
| α-D-Galactopyranose-phosphate di-potassium salt dihydrate | P0001 | C6H11K2O9P. 2H2O | 372,36 | 19046-60-7 |
| α-D-Glucopyranose-phosphate di-potassium salt dihydrate | P0002 | C6H11K2O9P. 2H2O | 372,36 | 5996-14-5 |
| α-D-Mannopyranose-phosphate di-potassium salt dihydrate | P0003 | C6H11K2O9P. 2H2O | 372,36 | 71888-67-0 |
| N-Acetyl-D-galactosamine (2-Acetamido-2-deoxy-D-galactose, GalNAc) | S96001 | C8H15NO6 | 221,21 | 1811-31-0 |
| N-Acetyl-D-glucosamine (2-Acetamido-2-deoxy-D-glucose, GlcNAc) | S93002 | C8H15NO6 | 221,21 | 7512-17-6 |
| 2-Acetamido-2-deoxy-β-D-glucopyranosylamin | S98003 | C8H16N2O5 | 220,21 | 18615-50-4 |
| N-Acetyl-D-mannosamine x H2O (2-Acetamido-2-deoxy-D-mannose monohydrate, D-ManAc x H2O) | S94004 | C8H17NO7 | 239,23 | 7772-94-3 |
| 1,3,4,6-tetra-O-acetyl-β-D-GlcNAc (2-Acetamido-2-deoxy-1,3,4,6-tetra-O-acetyl-β-D-glucopyranose) | S94005 | C16H23NO10 | 389.36 | 7772-79-4 |
| 3,4,6-tri-O-acetyl-β-D-GlcNAc azide (2-Acetamido-3,4,6-tri-O-acetyl-2-deoxy-β-D-glucopyranosyl azide) | S96006 | C14H20N4O8 | 372,34 | 6205-69-2 |
| 3,4,6-tri-O-acetyl-α-D-GlcNAc chlorid (2-Acetamido-2-deoxy-3,4,6-tri-O-acetyl-2-deoxy-α-D-glucopyranosyl chlorid) | S97007 | C14H20CINO8 | 366,80 | 3068-34-6 |
| 1,3,4,6-tetra-O-acetyl-α-D-glucosamine x HCl (2-Amino-2-deoxy-1,3,4,6-tetra-O-acetyl-α-D-glucopyranose HCl) | S00116 | C14H22CINO9 | 383,79 | N/A |
| Allyl 2-acetamido-2-deoxy-α-D-glucopyranoside | S96008 | C11H19NO6 | 261,28 | 54400-75-8 |
| Allyl 2-acetamido-2-deoxy-β-D-glucopyranoside | S96009 | C11H19NO6 | 261,28 | 54400-77-0 |
| Allyl α-D-galactopyranoside | S96010 | C9H16O6 | 220,22 | 48149-72-0 |
| Allyl α-D-glucopyranoside | S98011 | C9H16O6 | 220,22 | 7464-56-4 |
| Allyl β-D-glucopyranoside | S98012 | C9H16O6 | 220,22 | 34384-797 |
| Allyl α-D-mannopyranoside | S11118 | C9H16O6 | 220,22 | 41308-76-3 |
| Allyl 2,3,4-tri-O-benzyl-α-D-glucopyranoside | S98013 | C30H34O6 | 490,60 | N/A |
| 1-Amino-1-deoxy-β-D-galactose (β-D-Galactopyranosylamine) | S99102 | C6H13NO5 | 179,17 | 50444-86-5 |
| 1,6-Anhydro-β-D-galactopyranose | S93014 | C6H10O5 | 162,14 | 644-76-8 |
| 1,6:3,4-Dianhydro-2-O-tosyl-β-D-galactopyranose | S97016 | C13H14O6s | 234,25 | 6167-32-4 |
| D-Arabinose | S93017 | C5H10O5 | 150,13 | 28697-53-2 |
| Arbutin (4-Hydroxyphenyl b-D-glucopyranoside, synthetic) | S96018 | C12H16O7 | 272,25 | 497-76-7 |
| 2-Azido-2-deoxy-1,3,4,6-tetra-O-acetyl-α-D-galactopyranose | S96021 | C14H19N3O9 | 373,32 | N/A |
| 2-Azido-2-deoxy-1,3,4,6-tetra-O-acetyl-α,β-D-galactopyranose | S97022 | C14H19N3O9 | 373,32 | N/A |
| 2-Azido-2-deoxy-1,3,4,6-tetra-O-acetyl-β-D-glucopyranose | S96024 | C14H19N3O9 | 373,32 | N/A |
| 2-Azido-2-deoxy-1,2‘,3,3‘,4‘,6,6‘-hepta-O-acetyl-α,β-lactose 2-Azido-2-deoxy-4-O-(2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl)-1,3,6-tri-O-acetyl-α,β-D-glucopyranose | S96025 | C26H35N3O17 | 661,58 | N/A |
| 2-Azido-2-deoxy-1,3,4,6-tetra-O-acetyl-α-D-mannopyranose | S97026 | C14H19N3O9 | 373,32 | N/A |
| Benzyl 4,6-O-benzylidene-α-D-GlcNAc | S97027 | C22H25NO6 | 399,45 | 13343-63-0 |
| Benzyl α-D-GlcNAc (Benzyl 2-acetamido-2-deoxy-α-D-glucopyranoside) | S97028 | C15H21NO6 | 311,34 | 13343-62-9 |
| Benzyl α-D-mannopyranoside | S97029 | C13H18O6 | 270,28 | 155548-45-5 |
| Cellobiose | S96030 | C12H22O11 | 342,30 | 528-50-7 |
| 6-Deoxy-1,2:3,4-di-O-isopropylidene-α-D-galactopyranose | S96032 | C12H20O5 | 244,29 | 4026-27-1 |
| 3,4-Di-O-acetyl-L-rhamnal (3,4-Di-O-acetyl-6-deoxy-L-glucal) | S94035 | C10H14O5 | 214.22 | 34819-86-8 |
| 1,4:3,6-Dianhydro-D-mannitol | S97037 | C6H10O4 | 146,15 | 641-74-7 |
| 1,2,3,4-Di-O-isopropylidene-α-D-galactopyranose | S95038 | C12H20O6 | 260.29 | 4064-06-6 |
| 1,2:5,6-Di-O-isopropylidene-α-D-glucofuranose | S00112 | C12H20O6 | 260,29 | 582-52-5 |
| 1,2:5,6-Di-O-isopropylidene-D-mannitol | S95039 | C12H22O6 | 262,31 | 1707-77-3 |
| 2,3:5,6-Di-O-isopropylidene-α-D-mannofuranose | S93040 | C12H20O6 | 260.29 | 14131-84-1 |
| 1,2:3,5-Di-O-isopropylidene-α-D-xylofuranose | S00110 | C11H18O5 | 230,26 | 20881-04-3 |
| D-Fucose (6-Deoxy-D-galactose) | S96042 | C6H12O6 | 164,16 [3615-37-0] | 3615-37-0 |
| L-Fucose (6-Deoxy-L-galactose) | S96043 | C6H12O6 | 164,16 | 2438-80-4 |
| D-Galactosamine x HCl | S95044 | C6H13NO5 x HCl | 215.64 | 1172-03-8 |
| D-Glucosamine x HCl | S93045 | C6H13NO5 x HCl | 215.64 | 66-84-2 |
| L-Glucose | S94046 | C6H12O6 | 180.16 | 921-60-8 |
| 2,3,3’,4,6,6’-Hexa-O-acetyl-lactal | S97036 | N/A | N/A | |
| 1,2-O-Isopropylidene-α-D-glucofuranose | S00113 | C9H16O6 | 220,22 | 18549-40-1 |
| Isopropyl-β-D-thiogalactoside IPTG (lactose based) | S02122-L | C9H18O5S | 238,31 | 367-93-1 |
| Isopropyl-β-D-thiogalactoside IPTG (on plant based) | S02122-P | C9H18O5S | 238,31 | 367-93-1 |
| 3,4-O-Isopropylidene-D-mannitol | S94048 | C9H18O6 | 222,22 | 369-84-4 |
| 1,2-O-Isopropylidene-α-D-xylofuranose | S00111 | C8H14O5 | 190,20 | 20031-21-4 |
| D-Lyxose | S96051 | C5H10O5 | 150,13 | 1114-34-7 |
| L-Lyxose | S96052 | C5H10O5 | 150,13 | 1949-78-6 |
| Maltose monohydrate | S98053 | C12H22O11H2O | 360,32 | 6363-53-7 |
| β-Maltose octaacetate | S98054 | C28H38O19 | 678,63 | 22352-19-8 |
| D-Mannose | S93057 | C6H12O6 | 180.16 | 3458-28-4 |
| L-Mannose | S94058 | C6H12O6 | 180.16 | 10030-80-5 |
| Methyl 4,6-O-benzylidene-β-D-galactopyranoside | S96060 | C14H18O6 | 282,30 | 6988-39-2 |
| Methyl 4,6-O-benzylidene-α-D-glucopyranoside | S97061 | C14H18O6 | 282,30 | 3162-96-7 |
| Methyl 4,6-O-benzylidene-β-D-glucopyranoside | S98062 | C14H18O6 | 282,30 | 6988-39-2 |
| Methyl 6-deoxy-α-L-mannopyranoside (Methyl a-L-rhamnopyranoside) | S96063 | C7H14O5 | 178,19 | 15814-59-2 |
| Methyl α-D-fucopyranoside | S96064 | C7H14O5 | 178,19 | 1128-40-1 |
| Methyl α-L-fucopyranoside | S96065 | C7H14O5 | 178,19 | 14687-15-1 |
| Methyl β-D-galactopyranoside | S96066 | C7H14O6 | 194,18 | 1824-94-8 |
| Methyl β-D-glucopyranoside hemihydrate | S96067 | C7H14O6 | 194,18 | 7000-27-3 |
| Methyl β-D-ribopyranoside | S97068 | C6H12O5 | 164,16 | 17289-61-1 |
| Methyl 2,3,5-tri-O-benzoyl-α-D-arabinofuranoside | S98069 | C27H24O8 | 476,49 | N/A |
| 1,2,3,4,6-Penta-O-acetyl-β-D-galactopyranose | S95072 | C16H22O11 | 390,35 | 4163-60-4 |
| 1,2,3,4,6-Penta-O-acetyl-α-D-mannopyranose | S99070 | C16H22O11 | 390,35 | 4163-65-9 |
| D-Raffinose pentahydrate | S96074 | C18H32O16 5H2O | 594,53 | 17629-30-0 |
| L-Rhamnose monohydrate | S94075 | C6H14O6 | 182.17 | 10030-85-0 |
| D-Ribose | S93076 | C5H10O5 | 150.13 | 50-69-1 |
| L-Ribose | S93077 | C5H10O5 | 150.13 | 24259-59-4 |
| D-Tagatose | S93079 | C6H12O6 | 180.16 | 87-81-0 |
| α-D-Talose | S93080 | C6H12O6 | 180.16 | 2595-98-4 |
| 2,3,4,6-Tetra-O-acetyl-β-D-galactopyranosyl azide | S96081 | C14H19N3O9 | 373,32 | 13992-26-2 |
| 2,3,4,6-Tetra-O-acetyl-α-D-galactopyranosyl bromide | S96082 | C14H19BrO9 | 411.21 | 3068-32-4 |
| 2,3,4,6-Tetra-O-acetyl-β-D-glucopyranosyl azide | S96083 | C14H19N3O9 | 373,32 | 13992-25-1 |
| 2,3,4,6-Tetra-O-acetyl-α-D-glucopyranosyl bromide | S94084 | C14H19BrO9 | 411.21 | 572-09-8 |
| 1,3,4,6-Tetra-O-acetyl-β-D-mannopyranose | S97086 | C14H20O10 | 348,31 | 18968-05-3 |
| 2,3,4,6-Tetra-O-acetyl-α-D-mannopyranose | S97087 | C14H20O10 | 348,31 | N/A |
| 1,2,3,5-Tetra-O-acetyl-β-D-ribofuranose | S94088 | C13H18O9 | 318.28 | 13035-61-5 |
| 2,3,4,6-Tetra-O-acetyl-1-thio-β-D-galactopyranose | S94089 | C14H20O9S | 364.37 | N/A |
| 2,3,4,6-Tetra-O-acetyl-1-thio-β-D-glucopyranose | S94090 | C14H20O9S | 364.37 | 19879-84-6 |
| 2,3,4,6-Tetra-O-benzyl-α-D-galactopyranose | S96091 | C34H3606 | 540.66 | 5308-25-7 |
| 2,3,4,6-Tetra-O-benzyl-α-D-glucopyranose | S93092 | C34H3606 | 540.66 | 4132-28-9 |
| 2,3,4,6-Tetra-O-benzyl-α-D-mannopyranose | S96093 | C34H3606 | 540.66 | 61330-61-8 |
| 1-Thio-β-D-galactose sodium salt | S96094 | C6H11NaO5S | 218,21 | 42891-22-5 |
| 1-Thio-β-D-glucose sodium salt dihydrate | S94095 | C6H11NaO5S x 2 H2O | 254.24 | 10593-29-0 |
| 3,4,6-Tri-O-acetyl-D-galactal | S94097 | C12H16O7 | 272.26 | 4098-06-0 |
| D-Turanose (α-D-Glcp(1-3)-D-fructose) | S93100 | C12H22O11 | 342.30 | 547-25-1 |
| D-Xylose | S93101 | C5H10O5 | 150.13 | 58-86-6 |
| 1,6-Anhydro-β-D-glucopyranose (Levoglucosan) | S93015 | C6H10O5 | 162,14 | 498-07-7 |
| 2-Azido-2-deoxy-1,3,4,6-tetra-O-acetyl-α-D-glucopyranose | S96023 | C14H19N3O9 | 373,32 | N/A |
我们承诺:
(1)专业的服务:为您提供包括购买咨询、技术支持及实验方案制定在内的全方位服务;
(2)迅捷的货期:利用国际化的物流平台,大大缩短产品从厂家到最终用户的时间;
(3)过硬的品质:确保正品、质量和售后,多年客户积累,口碑保证。
公司简介:
艾美捷科技有限公司经营范围涵盖分子生物学试剂、免疫学试剂、细胞生物学试剂、蛋白质研究试剂、微生物学试剂、化学及生化试剂、材料学试剂、天然提取物、仪器设备等9大门类,累计约10万余种产品,充分满足不同客户的个性化需求;公司代理国外50余种一线品牌试剂,以“高性价比、迅捷的物流速度、专业的技术支持”,让客户充分享受全球化带来的便利;公司还增加了基因编辑、蛋白表达、细胞鉴定等定制项目,大大提升了为客户服务能力。“不忘初心,方得始终”,艾美捷科技将继续秉持“专心、专业、为您”的宗旨,以客户为根本,以诚信为基础,持续地为各界客户提供更加优质的产品和服务。
Glycon Biochemicals GmbH; Glycon Biochem; Glycon; S20031; S97085; S10191; S10192; S10189; S03293; S05174; S02174; D-20054; D-20055; D-20056; D97011; D20034; D99014; D07033; D97001; D97001-C; D99011; D99011-C; D99006; D11023; D99007; D99019-C; D99020; D20018; D14001; D20020; D20015; D20015-C; D99003; D99003-C; D99012; D99012-C; D97002-C; D20016; D20016-C; D20028-C; D20040-C; D20029-C; D97002; S02122; D99013; D20014; D14038-C; D20021; D20022-C; D99013-C; D20014-C; D98004; D99005; D99008; D20038; D20041; D20033; D20035; D20039; D20032; D20031; D20030; D71111; S98001; D20036; D99009; D99010; S10197; S10195; S10196; S10190; S10198; S10194; S10199; S01241; P0001; P0002; P0003; S96001; S93002; S98003; S94004; S94005; S96006; S97007; S00116; S96008; S96009; S96010; S98011; S98012; S11118; S98013; S99102; S93014; S97016; S93017; S96018; S96021; S97022; S96024; S96025; S97026; S97027; S97028; S97029; S96030; S96032; S94035; S97037; S95038; S00112; S95039; S93040; S00110; S96042; S96043; S95044; S93045; S94046; S97036; S00113; S02122-L; S02122-P; S94048; S00111; S96051; S96052; S98053; S98054; S93057; S94058; S96060; S97061; S98062; S96063; S96064; S96065; S96066; S96067; S97068; S98069; S95072; S99070; S96074; S94075; S93076; S93077; S93079; S93080; S96081; S96082; S96083; S94084; S97086; S97087; S94088; S94089; S94090; S96091; S93092; S96093; S96094; S94095; S94097; S93100; S93101; S93015; S96023; 10030-80-5; 10030-85-0; 10593-29-0; 106402-05-5; 106402-05-5; 111-03-5; 1114-34-7; 1128-40-1; 115457-83-5; 116183-64-3; 1172-03-8; 13035-61-5; 13343-62-9; 13343-63-0; 13992-25-1; 13992-26-2; 14131-84-1; 146801-07-2; 14687-15-1; 148565-58-6; 155548-45-5; 15814-59-2; 1643-20-5; 1707-77-3; 17289-61-1; 17629-30-0; 1811-31-0; 1824-94-8; 18449-82-6; 18549-40-1; 18615-50-4; 18968-05-3; 19046-60-7; 19327-39-0; 1949-78-6; 19879-84-6; 20031-21-4; 20881-04-3; 22352-19-8; 24259-59-4; 2438-80-4; 25339-99-5; 253678-64-7; 253678-65-8; 253678-67-0; 253678-67-0; 2595-98-4; 26183-52-81; 28697-53-2; 29557-51-5; 29781-80-4; 29836-26-8; 29836-26-8; 3055-98-9; 3055-99-0; 3068-32-4; 3068-34-6; 3162-96-7; 34384-797; 3458-28-4; 34819-86-8; 3615-37-0; 367-93-1; 367-93-1; 367-93-1; 369-84-4; 4026-27-1; 4064-06-6; 4098-06-0; 41308-76-3; 4132-28-9; 4163-60-4; 4163-65-9; 48149-72-0; 497-76-7; 498-07-7; 50444-86-5; 50-69-1; 5168-89-8; 5274-68-0; 528-50-7; 5308-25-7; 54400-75-8; 54400-77-0; 547-25-1; 572-09-8; 58066-85-6; 582-52-5; 58846-77-8; 58-86-6; 59080-45-4; 59122-55-3; 5996-14-5; 61330-61-8; 6167-32-4; 6205-69-2; 6363-53-7; 641-74-7; 644-76-8; 6540-99-4; 66-84-2; 69227-93-6; 69227-93-6; 6988-39-2; 6988-39-2; 69984-73-2; 69984-73-2; 7000-27-3; 70005-86-6; 70504-28-8; 71888-67-0; 7464-56-4; 7512-17-6; 75621-03-3; 7772-79-4; 7772-94-3; 77733-28-9; 78617-12-6; 82473-24-3; 82494-08-4; 82494-09-5; 82494-09-5; 85261-19-4; 85261-19-4; 85316-98-9; 85618-20-8; 85618-20-8; 85618-21-9; 85618-21-9; 85775-42-4; 870287-95-9; 87-81-0; 9043-30-5; 921-60-8; 93911-12-7; 93911-12-7; 98064-96-1; 98854-15-0; 98854-16-1

艾美捷科技代理MACHEREY-NAGEL品牌。
德国MN(Macherey-Nagel)(简称MN)成立于1911年是一家历史悠久的全球知名企业,专注于实验室耗材、快速检测产品及分析技术的研发与生产。从1993年起,MN公司成功研发了各种核酸分子分离和蛋白纯化的试剂盒和耗材,包括质粒抽提、PCR产物纯化和胶回收、RNA纯化、基因组DNA抽提、病毒核酸纯化试剂盒,以及His/GST标签蛋白纯化柱等。其产品以高品质、创新性和可靠性著称,广泛应用于环境监测、食品检测、医疗诊断、制药及科研领域。
MN品牌以多样化的产品线和创新技术满足不同领域需求:
● 实验室耗材:
滤纸、色谱柱、固相萃取柱(SPE)、微孔滤膜等。
特色:高纯度材料、精准分离性能,适用于复杂样品前处理。
● 快速检测产品:
试纸、试剂盒(如水质检测盒、食品安全检测盒)。
优势:操作简便、快速出结果,适用于现场检测。
● 诊断与医疗产品:
血液检测试纸、尿液分析试纸等,被医院和实验室广泛采用。
● 环境监测解决方案:
针对水质、空气污染等开发的高灵敏度检测工具。
更多详情请咨询→

全国免费热线:400-6800-868
直拨专线:132-6921-9473
客服QQ一:17754422825;
客服QQ二:18771149750
" data-original="http://genvivo.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="艾美捷科技代理MACHEREY-NAGEL(德国MN)品牌"> 艾美捷科技代理MACHEREY-NAGEL(德国MN)品牌

Illumina公司,基因组学研究领域的技术与市场领导者。借助新一代测序(NGS)与基因芯片(MicroArray)技术与平台,秉承“解锁基因组奥秘,推动人类健康事业”的愿景,为全球科研、医疗、制药、公共卫生等领域提供基因组学完整解决方案。Illumina公司主要提供Sequencing Kits、Library Preparation Kits、Cluster Generation & Sequencing Reagents、Microarray Kits、Clinical Research Products和Informatics Products等类型的产品。
Illumina的主要产品包括:
(1)Browse by Area of Interest:
Cancer Genomics Products
Reproductive Health Products
Microbial Genomics Products
Complex Disease Genomics Products
Genetic Health Products
Forensic Genomics Products
Agrigenomics Products
Genomics in Drug Development Products
(2)Browse by System:
HiSeq 2500 Products
HiSeq 3000/HiSeq 4000 Products
HiSeq X Five/HiSeq X Ten Products
iScan Products
iSeq Products
MiniSeq Products
MiSeq Products
MiSeqDx Products
MiSeq FGx Products
NextSeq Products
NovaSeq Products
<更多详情请联系
艾美捷科技有限公司
全国服务热线:400-6800-868
邮箱:sales@amyjet.com
网站:www.amyjet.com
< " data-original="http://genvivo.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="Illumina"> Illumina
Columbia Biosciences 公司成立于2007年,主要生产天然荧光蛋白、抗体交联物及检测试剂盒。Columbia Biosciences具有成熟的,对微藻生物的培养、分离、纯化、及藻类荧光蛋白基团接合技术,并将其应用于生命科学产品、诊断工具中,并推广到全世界。
Columbia Biosciences, founded in 2007, manufactures natural fluorescent proteins, antibody conjugates and assay kits. Columbia's expertise lies in the ability to integrate microalgae cultivation with the isolation, purification and conjugation of algal protein fluorophores. The company's fluorophores are integrated into a large number of life science products and diagnostic tools and, are distributed globally.
Columbia Biosciences的主要产品包括:
Cyclic AMP Kit
PHYCOBILIPROTEINS AND PERCP
TR-FRET REAGENTS
ANTIBODY CONJUGATES
Conjugation Kits
Europium Conjugates
Isotype Controls
POC Reagents
" data-original="http://genvivo.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="Columbia Biosciences"> Columbia Biosciences
艾美捷科技代理Berry & Associates全系列修饰核苷酸等
美国 Berry & Associates 公司成立于1989年,提供近200种亚磷酰胺和核苷酸合成用固相交联单体,以及数百种核苷、核苷酸、糖类、荧光标记物、淬灭剂和杂环化合物。
Founded in 1989 with roots in the nucleoside field, Berry & Associates soon moved into the chemistry of nucleic acids, resulting in a current portfolio of nearly 200 phosphoramidites and solid phase-linked monomers for oligonucleotide synthesis as well as hundreds of nucleosides, nucleotides, carbohydrates, spacers, fluorescent markers, quenchers, and heterocycles - all proudly made at our facility just outside of Ann Arbor, Michigan. Although our company is small, the credentials of our highly trained staff of chemists include over 400 publications and 80 patents in synthetic organic and medicinal chemistry. High quality chemicals, timeliness, and personalized service are the hallmarks of Berry & Associates.







Berry & Associates的主要产品包括:
| 产品名称 | 产品编号 | 纯度 | 规格 |
| 2',3'-Dideoxyadenosine | PR 3495 | ≥95% | 25 mg; 100 mg |
| 2'-3'-Dideoxyguanosine | PR 3505 | ≥95% | 25 mg; 100 mg |
| 2',3'-Dideoxyinosine | PR 3727 | ≥97% | 100 mg; 1 g |
| 3'-Deoxythymidine | PY 7277 | ≥95% | 50 mg; 100 mg |
| 2',3'-Dideoxyuridine | PY 7278 | ≥97% | 100 mg; 500 mg |
| 2',3'-Didehydro-2',3'-dideoxyuridine | PY 7279 | ≥97% | 25 mg; 100 mg |
| 2',3'-Dideoxycytidine | PY 7325 | ≥95% | 50 mg; 100 mg |
| 2-Aminoadenosine (2,6-Diaminopurine riboside) | PR 3030 | ≥97% | 2 g; 10 g |
| 2-Amino-2'-deoxyadenosine | PR 3060 | ≥97% | 1 g; 5 g |
| 2-Amino-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-deoxyadenosine | PR 3080 | ≥95% | 100 mg; 1 g |
| 2-Amino-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3090 | ≥97% | 250 mg; 1 g |
| 2-Amino-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3110 | ≥95% | 250 mg; 1 g |
| 2-Amino-N2-isobutyryl-2'-deoxyadenosine | PR 3130 | ≥95% | 100 mg; 1 g |
| 2-Amino-N2-O-methyladenosine | PR 3150 | ≥97% | 1 g; 10 g |
| 2-(Dimethylaminomethylidene)amino-6-methoxylamino-9-(β-D-2-deoxyribofuranosyl)purine | PR 3670 | ≥95% | 100 mg; 1 g |
| 2-Amino-9-(β-D-2'-deoxyribfuranosyl)purine | PR 3070 | ≥97% | 25 mg; 100 mg |
| 2-Amino-9-(2-O-methyl-β-D-ribofuranosyl)purine | PR 3160 | ≥97% | 100 mg; 250 mg |
| 2-Amino-9-(β-D-ribofuranosy)purine Hemihydrate | PR 3180 | ≥97% | 25 mg; 100 mg |
| 2-(Dimethylaminomethylidene)amino-9-(β-D-2-deoxyribofuranosyl)purine | PR 3680 | ≥97% | 100 mg; 1 g |
| 6-N-Acyl-6-N-methyl-2'-deoxyadenosine | PR 3006 | ≥95% | 25 mg; 100 mg |
| 8-Amino-2'-deoxyadenosine | PR 3115 | ≥97% | 10 mg; 100 mg |
| N6-(6-Aminohexyl)-2'-deoxyadenosine | PR 3120 | ≥90% | 100 mg; 1 g |
| 8-Azido-2'-deoxyadenosine | PR 3125 | ≥97% | 10 mg; 100 mg |
| N6-Benzoyl-8-benzyloxy-2'-deoxyadenosine | PR 3230 | ≥95% | 50 mg; 250 mg |
| N6-Benzoyl-5'-O-(dimethoxytrityl)-8-oxo-2'-deoxyadenosine | PR 3260 | ≥95% | 100 mg; 1 g |
| N6-Benzoyl-8-oxo-2'-deoxyadenosine | PR 3270 | ≥97% | 100 mg; 1 g |
| 8-Benzyloxy-2'-deoxyadenosine | PR 3280 | ≥97% | 100 mg; 1 g |
| 8-Bromo-2'-deoxyadenosine | PR 3290 | ≥90% | 2 g; 10 g |
| 8-Bromo-N6-(dimethylaminomethylidene)-2'-deoxyadenosine | PR 3320 | ≥95% | 100 mg; 1 g |
| 8-Bromo-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-2'-deoxyadenosine | PR 3340 | ≥97% | 0g (discontinued); |
| 2'-Deoxyadenosine Monohydrate | PR 3445 | ≥97% | 25 g; 100 g |
| 2',3'-Dideoxyadenosine | PR 3495 | ≥95% | 25 mg; 100 mg |
| 2-Fluoro-2'-deoxyadenosine | PR 3496 | ≥97% | 25 mg; 1 g |
| 8-Oxo-2'-deoxyadenosine | PR 3705 | ≥95% | 25 mg; 250 mg |
| N6-Methyl-2'-deoxyadenosine | PR 3740 | ≥97% | 100 mg; 1 g |
| 4-Chloro-1-(2-deoxy-β-D-ribofuranosyl)-7-methyl-1H-imidazo[4,5-c]pyridine | PRA 10012 | ≥95% | 10 mg; 50 mg |
| 3-Deaza-3-methyl-2'-deoxyadenosine | PRA 10013 | ≥97% | 10 mg; 25 mg |
| 5'-O-Dimethoxytrityl-N6-(N,N-dimethylaminomethylene)-8-aza-7-deaza-2'-deoxyadenosine | PRA 10019 | ≥97% | 500 mg; 1 g |
| 7-(3-Nitrophenyl)-7-deaza-2'-deoxyadenosine | PRA 10032 | ≥95% | 10 mg; 50 mg |
| 5-Iodo-2'-deoxytubercidin | PRA 10036 | ≥95% | 10 mg; 50 mg |
| 8-Allyloxy-2'-deoxyguanosine | PR 3010 | ≥90% | 0Discontinued; |
| 8-Allyloxy-N2-(dimethylaminomethylidene)-2'-deoxyguanosine | PR 3015 | ≥90% | 1 g; 10 g |
| 8-Allyloxy-N2-isobutyryl-2'-deoxyguanosine | PR 3020 | ≥90% | 1 g; 10 g |
| 5'-Azido-5'-deoxyguanosine | PR 3225 | ≥90% | 5 mg; 10 mg |
| 8-Benzyloxy-N2-isobutyryl-2'-deoxyguanosine | PR 3285 | ≥90% | 1 g; 10 g |
| 8-Bromo-2'-deoxyguanosine | PR 3300 | ≥90% | 1 g; 5 g |
| 8-Bromo-5'-O-(dimethyoxytrityl)-N2-(dimethyl-aminomethylidene)-2'-deoxyguanosine | PR 3310 | ≥97% | 500 mg; 1 g |
| 8-Bromo-N2-(dimethylaminomethylidene)-2'-deoxyguanosine | PR 3330 | ≥90% | 250 mg; 1 g |
| 5'-O-Dimethoxytrityl-N2-(dimethylaminomethylidene)-8-ethenyl-2'-deoxyguanosine | PR 3335 | ≥95% | 100 mg; 1 g |
| 2'-Deoxyguanosine monohydrate | PR 3452 | ≥97% | 10 g; 100 g |
| α-2'-Deoxyguanosine | PR 3455 | ≥97% | 10 mg; 100 mg |
| 2'-Deoxyisoguanosine | PR 3465 | ≥97% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-N2-ethyl-2'-deoxyguanosine | PR 3600 | ≥97% | 100 mg; 1 g |
| 3',5'-Di-O-acetyl-2'-deoxyguanosine | PR 3605 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3610 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-N2-methyl-2'-deoxy-guanosine | PR 3630 | ≥97% | 100 mg; 1 g |
| N2-Ethyl-2'-deoxyguanosine | PR 3700 | ≥95% | 25 mg; 100 mg |
| 5'-O-Dimethoxytrityl-N2-(trifluoroacetamido)hexyl-2'-deoxyguanosine | PR 3701 | ≥95% | 25 mg; 100 mg |
| 8-Oxo-2'-deoxyguanosine | PR 3710 | ≥97% | 25 mg; 250 mg |
| 8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3720 | ≥90% | 100 mg; 1 g |
| N2-Isobutyl-2'-deoxyguanosine | PR 3745 | ≥97% | 10 mg; 100 mg |
| N1-Methyl-2'-deoxyguanosine | PR 3748 | ≥97% | 25 mg; 1 g |
| N2-Methyl-2'-deoxyguanosine | PR 3750 | ≥97% | 25 mg; 100 mg |
| O6-Methyl-2'-deoxyguanosine | PR 3755 | ≥90% | 5 mg; 25 mg |
| 6-Thio-2'-deoxyguanosine | PR 3845 | ≥97% | 10 mg; 100 mg |
| 7-Methyl-7-deaza-2'deoxyguanosine | PRA 10042 | ≥97% | 10 mg; 50 mg |
| 2'-Deoxypseudoguanosine | PRA 10103 | ≥97% | 10 mg; 50 mg |
| 2'-Deoxypseudoisoguanosine | PRA 10104 | ≥97% | 10 mg; 100 mg |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| 2-Amino-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3090 | ≥97% | 250 mg; 1 g |
| 2-Amino-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3110 | ≥95% | 250 mg; 1 g |
| 2-Amino-N2-O-methyladenosine | PR 3150 | ≥97% | 1 g; 10 g |
| 2',3'-Di-O-methyladenosine | PR 3540 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-2'-O-methylinosine | PR 3640 | ≥97% | 1 g; |
| N6-Methyl-2'-O-Methyladenosine | PR 3733 | ≥97% | 50 mg; 100 mg |
| 2'-O-Methyladenosine | PR 3734 | ≥97% | 1 g; |
| 2'-O-Methylguanosine | PR 3760 | ≥97% | 1 g; 10 g |
| 2'-O-Methylinosine | PR 3770 | ≥97% | 500 mg; 1 g |
| N4-Acetyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7010 | ≥95% | 0 g DISCONTINUED; |
| N4-Acetyl-5'-methyl-2'-O-methylcytidine | PY 7020 | ≥97% | 0 g DISCONTINUED; |
| N4-Benzoyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7100 | ≥95% | 100 mg; 1 g |
| N4-Benzoyl-2'-O-methylcytidine | PY 7110 | ≥97% | 500 mg; 1 g |
| 3',5'-Di-O-acetyl-5-fluoro-O4-(2,4,6-trimethylphenyl)-2'-O-methyluridine | PY 7290 | ≥95% | 500 mg; 1 g |
| 3',5'-Di-O-acetyl-5-fluoro-2'-O-methyluridine | PY 7300 | ≥97% | 50 mg; 250 mg |
| 3',5'-Di-O-benzoyl-5-fluoro-2'-O-methyluridine | PY 7320 | ≥97% | 500 mg; 1 g |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-iodo-2'-O-methylcytidine | PY 7350 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-O-methylcytidine | PY 7360 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5-iodo-2'-O-methylcytidine | PY 7370 | ≥97% | 0 DISCONTINUED; |
| 5'-O-(Dimethoxytrityl)-5-fluoro-2'-O-methyluridine | PY 7420 | ≥95% | 100 mg; 500 mg |
| 5'-O-(Dimethoxytrityl)-5-iodo-2'-O-methyluridine | PY 7460 | ≥97% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-2'-O-methyluridine | PY 7470 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-2'-O-methyluridine | PY 7480 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-O-methyluridine | PY 7500 | ≥95% | 25 mg; 100 mg |
| 5-Fluoro-2'-O-methyluridine | PY 7570 | ≥97% | 50 mg; 100 mg |
| 5-Fluoro-2'-O-methyl-4-thiouridine | PY 7575 | ≥97% | 10 mg; 100 mg |
| 5-Fluoro-2'-O-methyl-4-(methylithio)uridine | PY 7577 | ≥97% | 10 mg; 100 mg |
| 5-Iodo-2'-O-methylcytidine | PY 7620 | ≥90% | 20 mg; 100 mg |
| 5-Iodo-2'-O-methyluridine | PY 7630 | ≥97% | 100 mg; 1 g |
| 2'-O-Methylcytidine | PY 7636 | ≥97% | 1 g; 5 g |
| 5-Methyl-2'-O-methylcytidine | PY 7640 | ≥97% | 100 mg; 500 mg |
| 5-Methyl-2'-O-methyluridine | PY 7650 | ≥97% | 100 mg; 1 g |
| 5-(1-Propynyl)-2'-O-methylcytidine | PY 7660 | ≥95% | 10 mg; 50 mg |
| 5-(1-Propynyl)-2'-O-methyluridine | PY 7670 | ≥97% | 10 mg; 25 mg |
| 2'-O-Methyluridine | PY 7690 | ≥97% | 5 g; |
| 5'-O-Acetyl-3'-azido-N2-palmitoyl-2',3'-dideoxy-guanosine | PR 3000 | ≥97% | 25 mg; 250 mg |
| 3'-Azido-N6-benzoyl-2',3'-dideoxyadenosine | PR 3200 | ≥90% | 50 mg; 250 mg |
| 3'-Azido-2',3'-dideoxyadenosine | PR 3210 | ≥97% | 10 mg; 25 mg |
| 3'-Azido-2',3'-dideoxyguanosine | PR 3220 | ≥97% | 10 mg; 25 mg |
| 3'-Azido-3'-deoxythymidine (AZT) | PY 7065 | ≥97% | 500 mg; 1 g |
| 3'-Azido-3'-deoxy-5'-O-methylthymidine | PY 7075 | ≥97% | 0 g DISCONTINUED; |
| 3'-Azido-2',3'-dideoxy-5-bromouridine | PY 7286 | ≥97% | 10 mg; 50 mg |
| N6-Benzoyl-3'-deoxyadenosine | PR 3240 | ≥97% | 100 mg; 1 g |
| N6-Benzoyl-5'-O-(dimethoxytrityl)-3'-deoxyadenosine | PR 3250 | ≥97% | 100 mg; 1 g |
| 3'-Deoxyadenosine | PR 3430 | ≥97% | 10 mg; 100 mg |
| 3'-Deoxyguanosine | PR 3460 | ≥97% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-N2-(dimethylaminomethylidene)-3'-deoxyguanosine | PR 3590 | ≥97% | 100 mg; 1 g |
| N2-(Dimethylaminomethylidene)-3'-deoxyguanosine | PR 3690 | ≥97% | 20 mg; 100 mg |
| 2'-O-Acetyl-5'-O-benzoyl-5-methyl-3'-deoxyuridine | PY 7000 | ≥97% | 500 mg; 1 g |
| N4-Benzoyl-3'-deoxycytidine | PY 7080 | ≥97% | 20 mg; 100 mg |
| 3'-Deoxycytidine | PY 7220 | ≥97% | 20 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-3'-deoxyuridine | PY 7240 | ≥95% | 25 mg; 100 mg |
| 5-Methyl-3'-deoxyuridine | PY 7260 | ≥95% | 20 mg; 50 mg |
| 5'-O-(Dimethoxytrityl)-5,6-dihydro-2'-deoxyuridine | PY 7230 | ≥97% | 100 mg; |
| 5,6-Dihydro-2'-deoxyuridine | PY 7330 | ≥97% | 100 mg; |
| (5S)-5,6-Dihydrothymidine | PY 7340 | ≥97% | 20 mg; 100 mg |
| (5S)-5'-O-(Dimethoxytrityl)-5,6-dihydrothymidine | PY 7390 | ≥97% | 100 mg; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-O-methylcytidine | PY 7360 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-deoxycytidine | PY 7400 | ≥97% | 100 mg; 500 mg |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-deoxyuridine | PY 7490 | ≥95% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-O-methyluridine | PY 7500 | ≥95% | 25 mg; 100 mg |
| 5-(1-Propynyl)-2'-O-methylcytidine | PY 7660 | ≥95% | 10 mg; 50 mg |
| 5-(1-Propynyl)-2'-O-methyluridine | PY 7670 | ≥97% | 10 mg; 25 mg |
| 5-(1-Propynyl)-2'-deoxycytidine | PY 7700 | ≥90% | 5 mg; 10 mg |
| 5-(1-Propynyl)-2'-deoxyuridine | PY 7710 | ≥97% | 100 mg; 1 g |
| 2-Amino-6-chloro-9-(β-D-2-deoxyribofuranosyl)purine | PR 3040 | ≥97% | 1 g; |
| 2-Amino-6-chloro-9-(3,5-di-(p-toluoyl)-β-D-2-deoxyribofuranosyl)purine | PR 3045 | ≥95% | 1 g; |
| 2-Amino-6-chloro-9-(β-D-ribofuranosyl)purine | PR 3050 | ≥95% | 5 g; 25 g |
| 6-Chloro-9-(β-D-2-deoxyribofuranosyl)purine | PR 3370 | ≥97% | 100 mg; 1 g |
| 6-Chloro-9-(3,5-O-di-(p-toluoyl)-β-D-2-deoxyribofuranosyl)purine | PR 3380 | ≥90% | 100 mg; 1 g |
| 6-Chloro-9-(5-O-dimethoxytrityl-β-D-2-deoxyribofuranosyl)purine | PR 3390 | ≥97% | 0 g; |
| 6-Chloro-9-(β-D-ribofuranosyl)purine | PR 3400 | ≥97% | 5 g; 10 g |
| Adenosine | PR 3005 | ≥97% | 100 g; 1 kg |
| 8-Methyladenosine | PR 3007 | ≥95% | 25 mg; 100 mg |
| Vidarabine | PR 3008 | ≥97% | 1 g; 5 g |
| 2-Aminoadenosine (2,6-Diaminopurine riboside) | PR 3030 | ≥97% | 2 g; 10 g |
| N1-Methyladenosine hydroiodide | PR 3032 | ≥95% | 100 mg; 1 g |
| 2-Methyladenosine | PR 3035 | ≥97% | 10 mg; 25 mg |
| 5'-Chloro-5'-deoxyadenosine | PR 3360 | ≥97% | 100 mg; 1 g |
| N6-Methyladenosine | PR 3732 | ≥97% | 100 mg; 1 g |
| N6-Methyl-2'-O-Methyladenosine | PR 3733 | ≥97% | 50 mg; 100 mg |
| 3-Deaza-3-methyl-2'-deoxyadenosine | PRA 10013 | ≥97% | 10 mg; 25 mg |
| 7-Deazaadenosine (tubercidin) | PRA 10035 | ≥97% | 10 mg; 100 mg |
| 5-Iodo-2'-deoxytubercidin | PRA 10036 | ≥95% | 10 mg; 50 mg |
| 2-Amino-4-chloro-7-(β-D-2-deoxyribofuranosyl)pyrrolo[2,3-d]pyrimidine | PRA 10000 | ≥97% | 100 mg; 1 g |
| 2-Amino-4-methoxy-7-(β-D-2-deoxyribofuranosyl)pyrrolo[2,3-d]pyrimidine | PRA 10005 | ≥97% | 500 mg; 1 g |
| 4-Chloro-1-(β-D-2-deoxyribofuranosyl)imidazo[4,5-C]pyridine | PRA 10006 | ≥90% | 25 mg; 100 mg |
| 8-Azaadenosine | PRA 10007 | ≥97% | 20 mg; |
| 8-Aza-7-deaza-2'-deoxyadenosine (4-Amino-1-(2-deoxyribofuranosyl)pyrazolo[3,4-d]-pyrimidine) | PRA 10008 | ≥95% | 10 mg; 100 mg |
| 4-Chloro-1-(3,5-di-O-toluoyl-2-deoxy-β-D-ribofuranosyl)pyrazolo[3,4-d]pyrimidine | PRA 10009 | ≥95% | 100 mg; 1 g |
| N6-Benzoyl-7-deaza-2'-deoxyadenosine | PRA 10010 | ≥97% | 100 mg; 1 g |
| Allopurinol riboside | PRA 10011 | ≥97% | 25 mg; 1 g |
| 5'-O-Dimethoxytrityl-N6-(N,N-dimethylaminomethylene)-8-aza-7-deaza-2'-deoxyadenosine | PRA 10019 | ≥97% | 500 mg; 1 g |
| N6-Benzoyl-5'-O-(dimethoxytrityl)-7-deaza-2'-deoxyadenosine | PRA 10020 | ≥97% | 100 mg; 1 g |
| 3-Deaza-2'-deoxyadenosine | PRA 10025 | ≥97% | 25 mg; 100 mg |
| 7-Deaza-2'-deoxyadenosine | PRA 10030 | ≥97% | 100 mg; 1 g |
| 7-Deazaadenosine (tubercidin) | PRA 10035 | ≥97% | 10 mg; 100 mg |
| 5-Iodo-2'-deoxytubercidin | PRA 10036 | ≥95% | 10 mg; 50 mg |
| 7-Deaza-2'-deoxyguanosine | PRA 10040 | ≥97% | 100 mg; 1 g |
| 7-Deazaguanosine | PRA 10045 | ≥97% | 10 mg; 100 mg |
| 7-Deaza-2'-deoxyxanthosine | PRA 10050 | ≥97% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-7-deaza-2'-deoxyxanthosine | PRA 10055 | ≥97% | 100 mg; 1 g |
| 1-(β-D-2-Deoxyribofuranosyl)-5-nitroindole | PRA 10060 | ≥97% | 100 mg; 1 g |
| 1-(β-D-2-Deoxyribofuranosyl)-4-methylindole | PRA 10070 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-4-methylindole | PRA 10080 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-5-nitroindole | PRA 10090 | ≥97% | 100 mg; 1 g |
| 5-Iodotubercidin | PRA 10095 | ≥90% | 5 mg; 25 mg |
| 5'-O-(Dimethoxytrityl)-N2-(dimethylaminomethylidene)-7-deaza-2'-deoxyguanosine | PRA 10100 | ≥97% | 100 mg; 1 g |
| N2-(Dimethylaminomethylidene)-7-deaza-2'-deoxyguanosine | PRA 10110 | ≥97% | 100 mg; 1 g |
| Sangivamycin | PRA 10140 | ≥97% | 10 mg; 25 mg |
| Toyocamycin | PRA 10150 | ≥97% | 10 mg; 100 mg |
| Triciribine | PRA 10160 | ≥97% | 10 mg; |
| Tricyclic Nucleoside Phosphate | PRA 10162 | ≥95% | 10 mg; |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| Formycin A | PYA 11001 | ≥97% | 10 mg; |
| Formycin B | PYA 11002 | ≥97% | 10 mg; |
| dNaM | FC 8110 | ≥97% | 25 mg; 100 mg |
| 9-Deaza-2'-deoxyguanosine | PRA 10120 | ≥97% | 10 mg; 100 mg |
| 9-Deazaguanosine | PRA 10130 | ≥97% | 10 mg; 100 mg |
| 2-Chloro-6-(β-D-2-deoxyribofuranosyl)-3,5-diaminopyrazine | PYA 11000 | ≥97% | 10 mg; 25 mg |
| Formycin A | PYA 11001 | ≥97% | 10 mg; |
| Formycin B | PYA 11002 | ≥97% | 10 mg; |
| Pyrazofurin | PYA 11004 | ≥97% | 10 mg; |
| 2'-Deoxypseudoisocytidine | PYA 11005 | ≥97% | 10 mg; 100 mg |
| 2'-Deoxypseudouridine | PYA 11010 | Purity: ≥97% | 25 mg; |
| 5'-O-(Dimethoxytrityl)-N-(dimethylamino) methylidene-2'-deoxypseudoisocytidine | PYA 11035 | Purity: ≥97% | 50 mg; 100 mg |
| 1,3-Dimethyl-2'-deoxypseudouridine | PYA 11040 | ≥97% | 10 mg; 100 mg |
| 1,3-Dimethylpseudouridine | PYA 11050 | ≥97% | 10 mg; 50 mg |
| N1-Methylpseudouridine | PYA 11052 | ≥95% | 10 mg; 50 mg |
| N3-Methylpseudouridine | PYA 11054 | ≥97% | 10 mg; 25 mg |
| Showdomycin | PYA 11056 | ≥97% | 10 mg; |
| Pseudoisocytidine hydrochloride | PYA 11060 | ≥97% | 10 mg; 100 mg |
| Pseudothymidine | PYA 11070 | ≥97% | 10 mg; 100 mg |
| Pseudouridine | PYA 11080 | ≥97% | 10 mg; 50 mg |
| 3'-O-(t-Butyldimethylsilyl)-5'-oxo-2'-deoxy-8,5'-cycloadenosine | PR 3350 | ≥97% | 10 mg; |
| (5'S)-8,5'-Cycloadenosine | PR 3410 | ≥97% | 10 mg; 100 mg |
| (5'S)-2'-Deoxy-8,5'-cycloadenosine | PR 3420 | ≥97% | 10 mg; |
| 5'-Deoxy-8,5'-cycloadenosine | PR 3440 | ≥97% | 10 mg; 100 mg |
| 2',5'-Dideoxy-8,5'-cycloadenosine | PR 3500 | ≥97% | 10 mg; |
| 2',3'-O-Isopropylidene-5'-oxo-8,5'-cycloadenosine | PR 3730 | ≥97% | 10 mg; 100 mg |
| 5'-Oxo-8,5'-cycloadenosine | PR 3800 | ≥97% | 10 mg; 100 mg |
| 5'-Oxo-2'-deoxy-8,5'-cycloadenosine | PR 3810 | ≥97% | 10 mg; |
| N4-Acetyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7010 | ≥95% | 0 g DISCONTINUED; |
| N4-Acetyl-5'-methyl-2'-O-methylcytidine | PY 7020 | ≥97% | 0 g DISCONTINUED; |
| N4-Benzoyl-5-(furan-2-yl)-2'-deoxycytidine | PY 7054 | ≥97% | 25 mg; 100 mg |
| N4-Benzoyl-3'-deoxycytidine | PY 7080 | ≥97% | 20 mg; 100 mg |
| N4-Benzoyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7100 | ≥95% | 100 mg; 1 g |
| N4-Benzoyl-2'-O-methylcytidine | PY 7110 | ≥97% | 500 mg; 1 g |
| 5-Bromo-2'-deoxycytidine | PY 7115 | ≥97% | 1 g; 10 g |
| Cytidine | PY 7215 | ≥97% | 50 g; 500 g |
| 2'-Deoxycytidine | PY 7216 | ≥97% | 10 g; 50 g |
| 2'-Deoxycytidine Hydrochloride | PY 7217 | ≥97% | 5 g; 50 g |
| 5'-Azido-2',5'-dideoxycytidine | PY 7219 | ≥97% | 25 mg; 100 mg |
| 3'-Deoxycytidine | PY 7220 | ≥97% | 20 mg; 100 mg |
| N4-Ethyl-2'-deoxycytidine | PY 7245 | ≥97% | 100 mg; 250 mg |
| 5-Methyl-2'-deoxyisocytidine | PY 7255 | ≥95% | 500 mg; 1 g |
| 6-(β-D-2-Deoxyribofuranosyl)-3,4-dihydro-8H-pyrimido-[4,5-c][1,2]oxazin-7-one | PY 7270 | ≥97% | 20 mg; 50 mg |
| 2',3'-Dideoxycytidine | PY 7325 | ≥95% | 50 mg; 100 mg |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-iodo-2'-O-methylcytidine | PY 7350 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-O-methylcytidine | PY 7360 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5-iodo-2'-O-methylcytidine | PY 7370 | ≥97% | 0 DISCONTINUED; |
| 6-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-3,4-dihydro-8H-pyrimido-[4,5-c][1,2]oxazin-7-one | PY 7380 | ≥97% | 50 mg; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-deoxycytidine | PY 7400 | ≥97% | 100 mg; 500 mg |
| 5-O-(Dimethoxytrityl)-N4-dimethylaminomethylidene-5-iodo-2'-deoxycytidine | PY 7410 | ≥97% | 100 mg; |
| 6-(3,5-Di-O-(p-toluoyl)-β-D-2-deoxyribofuranosyl)-3,4-dihydro-8H-pyrimido[4,5-c][1,2]oxazin-7-one | PY 7540 | ≥95% | 250 mg; 500 mg |
| Cytidin-5-yl-methanesulfonate sodium salt hydrate | PY 7586 | ≥95% | 50 mg; 100 mg |
| 5-[(2-Cyanoethoxy)methyl]-2'-deoxycytidine | PY 7587 | ≥97% | 10 mg; 50 mg |
| 5-Hydroxymethyl-2'-deoxycytidine | PY 7588 | ≥97% | 50 mg; 100 mg |
| 5-Formyl-2'-deoxycytidine | PY 7589 | ≥97% | 5 mg; 10 mg |
| 5-Carboethoxy-2'-deoxycytidine | PY 7592 | ≥95% | 25 mg; 100 mg |
| 2'-Deoxycytidine-5-carboxylic acid, sodium salt | PY 7593 | ≥95% | 25 mg; 100 mg |
| 5-Hydroxy-2'-deoxycytidine | PY 7595 | ≥95% | 25 mg; 250 mg |
| 5-Hydroxymethylcytidine | PY 7596 | ≥97% | 50 mg; 100 mg |
| Cytidine-5-carboxylic acid, sodium salt | PY 7598 | ≥97% | 10 mg; 50 mg |
| 5-Formylcytidine | PY 7599 | ≥97% | 5 mg; 10 mg |
| 5-Iodo-2'-deoxycytidine | PY 7607 | ≥97% | 2 g; 10 g |
| 5-Iodocytidine | PY 7609 | ≥97% | 5 g; |
| 5-Iodo-2'-O-methylcytidine | PY 7620 | ≥90% | 20 mg; 100 mg |
| 5-Methyl-2'-deoxycytidine Hydrochloride | PY 7635 | ≥97% | 0.25 g; 1 g |
| 2'-O-Methylcytidine | PY 7636 | ≥97% | 1 g; 5 g |
| 5-Methylcytidine | PY 7637 | ≥97% | 1 g; 5 g |
| N4-Methylcytidine | PY 7638 | ≥97% | 25 mg; 100 mg |
| 5-Methyl-2'-O-methylcytidine | PY 7640 | ≥97% | 100 mg; 500 mg |
| 6-Methylcytidine | PY 7641 | ≥97% | 10 mg; 25 mg |
| 5-(1-Propynyl)-2'-O-methylcytidine | PY 7660 | ≥95% | 10 mg; 50 mg |
| 5-(1-Propynyl)-2'-deoxycytidine | PY 7700 | ≥90% | 5 mg; 10 mg |
| 2-Thiocytidine | PY 7721 | ≥97% | 10 mg; 100 mg |
| 2-Thio-2'-deoxycytidine | PY 7723 | ≥95% | 10 mg; 100 mg |
| 3'-Deoxy-3',4'-didehydrocytidine | PY 7790 | ≥95% | 10 mg; 25 mg |
| Pyrrolo-dC | PYA 11090 | ≥95% | 10 mg; 100 mg |
| 6-Methyl-3-(β-D-2-ribofuranosyl)pyrrolo[2,3-d]pyrimidin-2-one | PYA 11092 | ≥97% | 10 mg; 100 mg |
| 3-(5'-O-Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-6-methylpyrrolo[2,3-d]pyrimidin-2-one | PYA 11095 | ≥95% | 100 mg; 1 g |
| 3-(2'-Deoxy-β-D-2-ribofuranosyl)pyrido[2,3-d]pyrimidine-2,7(8H)-dione | PYA 11100 | ≥95% | 10 mg; 100 mg |
| 3,N4-Etheno-2'-deoxycytidine | PYA 11130 | ≥97% | 100 mg; 500 mg |
| N6-Benzoyl-8-oxo-2'-deoxyadenosine | PR 3270 | ≥97% | 100 mg; 1 g |
| (5'S)-8,5'-Cycloadenosine | PR 3410 | ≥97% | 10 mg; 100 mg |
| (5'S)-2'-Deoxy-8,5'-cycloadenosine | PR 3420 | ≥97% | 10 mg; |
| 5'-O-(Dimethoxytrityl)-8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3610 | ≥97% | 100 mg; 1 g |
| 8-Oxo-2'-deoxyadenosine | PR 3705 | ≥95% | 25 mg; 250 mg |
| 8-Oxo-2'-deoxyguanosine | PR 3710 | ≥97% | 25 mg; 250 mg |
| 8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3720 | ≥90% | 100 mg; 1 g |
| 8-Hydroxyguanosine | PR 3795 | ≥97% | 10 mg; 100 mg |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| 5-Aza-2'-deoxycytidine | PY 7105 | ≥95% | 25 mg; 100 mg |
| 5,6-Dihydro-5-aza-2'-deoxycytidine | PY 7106 | ≥97% | 25 mg; 100 mg |
| 5,6-Dihydro-2'-deoxyuridine | PY 7330 | ≥97% | 100 mg; |
| (5S)-5,6-Dihydrothymidine | PY 7340 | ≥97% | 20 mg; 100 mg |
| 5-Hydroxy-2'-deoxycytidine | PY 7595 | ≥95% | 25 mg; 250 mg |
| 5-Hydroxy-2'-deoxyuridine | PY 7597 | ≥95% | 25 mg; 250 mg |
| 5-(2-Hydroxyethyl)-2'-deoxyuridine | PY 7600 | ≥95% | 25 mg; 50 mg |
| 5-Hydroxymethyl-2'-deoxyuridine | PY 7605 | ≥95% | 25 mg; 250 mg |
| 6-Methylcytidine | PY 7641 | ≥97% | 10 mg; 25 mg |
| Nap-dU | PY 7735 | ≥97% | 10 mg; 25 mg |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| 3,N4-Etheno-2'-deoxycytidine | PYA 11130 | ≥97% | 100 mg; 500 mg |
| Pyrrolo-dC | PYA 11090 | ≥95% | 10 mg; 100 mg |
| 6-Methyl-3-(β-D-2-ribofuranosyl)pyrrolo[2,3-d]pyrimidin-2-one | PYA 11092 | ≥97% | 10 mg; 100 mg |
| 3-(5'-O-Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-6-methylpyrrolo[2,3-d]pyrimidin-2-one | PYA 11095 | ≥95% | 100 mg; 1 g |
| 3-(2'-Deoxy-β-D-2-ribofuranosyl)pyrido[2,3-d]pyrimidine-2,7(8H)-dione | PYA 11100 | ≥95% | 10 mg; 100 mg |
| 8-18O-Hydroxyguanosine | IOPR 3795 | ≥95% | 2 mg; 5 mg |
| 2'-Deoxyisoguanosine | PR 3465 | ≥97% | 10 mg; 100 mg |
| 5'-O-Dimethoxytrityl-N2-(trifluoroacetamido)hexyl-2'-deoxyguanosine | PR 3701 | ≥95% | 25 mg; 100 mg |
| N2-Dimethylguanosine | PR 3702 | ≥97% | 10 mg; 100 mg |
| Guanosine | PR 3703 | ≥97% | 100 g; 500 g |
| Isoguanosine | PR 3735 | ≥97% | 10 mg; 50 mg |
| O6-Methylguanosine | PR 3757 | ≥97% | 25 mg; 100 mg |
| 2'-O-Methylguanosine | PR 3760 | ≥97% | 1 g; 10 g |
| 7-Methyl-6-thioguanosine | PR 3790 | ≥75% | 25 mg; 100 mg |
| 8-Bromoguanosine | PR 3796 | ≥97% | 0 g; |
| 8-Benzyloxyguanosine | PR 3797 | ≥95% | 100 mg; 1 g |
| 7-Methyl-7-deaza-2'deoxyguanosine | PRA 10042 | ≥97% | 10 mg; 50 mg |
| 7-Deazaguanosine | PRA 10045 | ≥97% | 10 mg; 100 mg |
| 5-Amino-3-β-D-ribofuranosylthiazolo[4,5-d]pyrimidin-2,7(3H,6H)-dione | PRA 10047 | ≥97% | 10 mg; 100 mg |
| 2'-Deoxypseudoguanosine | PRA 10103 | ≥97% | 10 mg; 50 mg |
| 2'-Deoxypseudoisoguanosine | PRA 10104 | ≥97% | 10 mg; 100 mg |
| 1-(β-D-2-Deoxyribofuranosyl)-5-nitroindole | PRA 10060 | ≥97% | 100 mg; 1 g |
| 1-(β-D-2-Deoxyribofuranosyl)-4-methylindole | PRA 10070 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-4-methylindole | PRA 10080 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-5-nitroindole | PRA 10090 | ≥97% | 100 mg; 1 g |
| 2'-Deoxy-4-desmethylwyosine | PR 3450 | ≥95% | 100 mg; 500 mg |
| 2'-Deoxyinosine | PR 3463 | ≥97% | 10 g; 100 g |
| 5'-Azido-2',5'-dideoxyinosine | PR 3464 | ≥97% | 5 mg; 25 mg |
| 3',5'-Di-O-acetyl-2'-deoxyinosine | PR 3480 | ≥97% | 1 g; |
| 3',5'-Di-O-acetyl-O6-phenyl-2'-deoxyinosine | PR 3490 | ≥90% | 1 g; |
| 5'-O-(Dimethoxytrityl)-2'-O-methylinosine | PR 3640 | ≥97% | 1 g; |
| 5'-O-(Dimethoxytrityl)-O6-phenyl-2'-deoxyinosine | PR 3660 | ≥97% | 100 mg; 1 g |
| Inosine | PR 3725 | ≥97% | 100 g; 500 g |
| 2',3'-Dideoxyinosine | PR 3727 | ≥97% | 100 mg; 1 g |
| 2'-O-Methylinosine | PR 3770 | ≥97% | 500 mg; 1 g |
| 7-Methylinosine | PR 3780 | ≥95% | 100 mg; 250 mg |
| O6-Phenyl-2'-deoxyinosine | PR 3840 | ≥97% | 100 mg; 1 g |
| 2-Fluoro-6-O-(2-(4-nitrophenyl)ethyl)-2'-deoxyinosine | PR 3842 | ≥97% | 25 mg; |
| 5'-O-Dimethoxytrityl-2-fluoro-6-O-(2-(4-nitrophenyl)ethyl)-2'-deoxyinosine | PR 3843 | ≥90% | 25 mg; 100 mg |
| 2'-Deoxyisoguanosine | PR 3465 | ≥97% | 10 mg; 100 mg |
| N6-(Diisobutylaminomethylidene)-2'-deoxyisoguanosine | PR 3510 | ≥90% | 100 mg; 1 g |
| N6-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-O2-(diphenylcarbamoyl)-2'-deoxyisoguanosine | PR 3520 | ≥95% | 100 mg; 1 g |
| N6-(Diisobutylaminomethylidene)-O2-(diphenylcarbamoyl)-2'-deoxyisoguanosine | PR 3530 | ≥90% | 100 mg; 1 g |
| Isoguanosine | PR 3735 | ≥97% | 10 mg; 50 mg |
| d5SICS | FC 8120 | ≥97% | 25 mg; 100 mg |
| AICA Riboside (AICAR) | MN 20001 | ≥97% | 0 g (DISCONTINUED); |
| 2',3'-Di-O-methyladenosine | PR 3540 | ≥97% | 100 mg; 1 g |
| 2,6-Bis-O-[2-(4-nitrophenyl)ethyl]-2'-deoxyxanthosine | PR 3692 | ≥95% | 10 mg; 100 mg |
| 5-Amino-3-β-D-ribofuranosylthiazolo[4,5-d]pyrimidin-2,7(3H,6H)-dione | PRA 10047 | ≥97% | 10 mg; 100 mg |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| 3'-Deoxy-3',4'-didehydrocytidine | PY 7790 | ≥95% | 10 mg; 25 mg |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| tC Nucleoside | PYA 11110 | ≥97% | 50 mg; 100 mg |
| tCnitro Nucleoside | PYA 11115 | ≥95% | 5 mg; 25 mg |
| 2'-Deoxynebularine | PR 3470 | Purity: ≥97% | 100 mg; 1 g |
| 7-Methylinosine | PR 3780 | ≥95% | 100 mg; 250 mg |
| 7-Methyl-6-thioguanosine | PR 3790 | ≥75% | 25 mg; 100 mg |
| 1-(β-D-2-Deoxyribofuranosyl)-3-nitropyrrole | PYA 11020 | ≥97% | 50 mg; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-3-nitropyrrole | PYA 11030 | ≥95% | 100 mg; |
| Showdomycin | PYA 11056 | ≥97% | 10 mg; |
| Formycin A | PYA 11001 | ≥97% | 10 mg; |
| Formycin B | PYA 11002 | ≥97% | 10 mg; |
| Pseudouridine | PYA 11080 | ≥97% | 10 mg; |
| Pyrazofurin | PYA 11004 | ≥97% | 10 mg; |
| Toyocamycin | PRA 10150 | ≥97% | 10 mg; |
| 7-Deazaadenosine (tubercidin) | PRA 10035 | ≥97% | 10 mg; |
| Allopurinol riboside | PRA 10011 | ≥97% | 25 mg; |
| 5-Iodotubercidin | PRA 10095 | ≥90% | 5 mg; |
| Triciribine | PRA 10160 | ≥97% | 10 mg; |
| Tricyclic Nucleoside Phosphate | PRA 10162 | ≥95% | 10 mg; |
| 5-Amino-3-β-D-ribofuranosylthiazolo[4,5-d]pyrimidin-2,7(3H,6H)-dione | PRA 10047 | ≥97% | 10 mg; |
| 5'-Amino-5'-deoxythymidine | PY 7030 | ≥97% | 25 mg; 50 mg |
| O2,5'-Anhydrothymidine | PY 7060 | ≥95% | 500 mg; 1 g |
| 3'-Azido-3'-deoxythymidine (AZT) | PY 7065 | ≥97% | 500 mg; 1 g |
| 5'-Azido-5'-deoxythymidine | PY 7070 | ≥97% | 25 mg; 100 mg |
| 3'-Azido-3'-deoxy-5'-O-methylthymidine | PY 7075 | ≥97% | 0 g DISCONTINUED; |
| 3'-O-(t-Butyldimethylsilyl)-5'-deoxy-5'-(1,3-diphenyl-2-imidazolidinyl)thymidine | PY 7120 | ≥97% | 1 g; |
| 3'-O-(t-Butyldimethylsilyl)thymidine | PY 7130 | ≥95% | 500 mg; 1 g |
| 5'-O-(t-Butyldimethylsilyl)thymidine | PY 7140 | ≥97% | 5 g; 10 g |
| 3',5'-bis-O-(t-Butyldimethylsilyl)thymidine | PY 7150 | ≥97% | 1 g; 5 g |
| 3',5'-bis-O-(t-Butyldimethylsilyl)-O4-(2,4,6-triisopropylphenylsulfonyl)thymidine | PY 7160 | ≥95% | 100 mg; 500 mg |
| S4-(2-Cyanoethyl)-5'-O-(dimethoxytrityl)-4-thiothymidine | PY 7200 | ≥95% | 10 mg; 100 mg |
| S4-(2-Cyanoethyl)-4-thiothymidine | PY 7210 | ≥95% | 10 mg; 100 mg |
| 5'-Deoxy-5'-(1,3-diphenyl-2-imidazolidinyl)thymidine | PY 7250 | ≥97% | 1 g; |
| 3'-Deoxythymidine | PY 7277 | ≥95% | 50 mg; 100 mg |
| 1-(3,5-Di-O-acetyl-β-D-deoxyribofuranosyl)-4-(1,2,4-triazol-1-yl)-5-methylpyrmidin-2-one | PY 7315 | ≥90% | 1 g; 10 g |
| 2',3'-Didehydro-3'-deoxythymidine | PY 7328 | ≥95% | 10 mg; 100 mg |
| (5S)-5,6-Dihydrothymidine | PY 7340 | ≥97% | 20 mg; 100 mg |
| (5S,6R)-5',6'-Cyclo-5'-deoxy-5,6-dihydrothymidine | PY 7345 | ≥95% | 10 mg; 25 mg |
| (5S)-5'-O-(Dimethoxytrityl)-5,6-dihydrothymidine | PY 7390 | ≥97% | 100 mg; |
| 5'-O-(Dimethoxytrityl)-N3/O4-(toluoyl)-2-thiothymidine | PY 7510 | ≥97% | 50 mg; 100 mg |
| 2-O-Ethylthymidine | PY 7561 | ≥97% | 500 mg; 1 g |
| 5'-Iodo-5'-deoxythymidine | PY 7610 | ≥97% | 250 mg; 1 g |
| 5'-O-Methylthymidine | PY 7680 | ≥95% | 50 mg; 100 mg |
| 2-Thiothymidine | PY 7725 | ≥95% | 20 mg; 100 mg |
| Thymidine | PY 7727 | ≥97% | 25 g; 250 g |
| 5'-O-(p-Toluenesulfonyl)thymidine | PY 7740 | ≥97% | 5 g; |
| 3-(2-Cyanoethyl)thymidine | PY 7742 | ≥95% | 10 mg; 25 mg |
| 5'-Trifluoroacetamido-5'-deoxythymidine | PY 7750 | ≥97% | 50 mg; |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| 6-Methyl-3-(β-D-2-deoxyribofuranosyl)furano-[2,3-d]pyrimidin-2-one | PYA 11055 | ≥97% | 5 mg; 25 mg |
| 6-Azathymidine | PYA 11058 | ≥95% | 25 mg; 100 mg |
| NPOM-Caged-dT CEP | BA 0317 | ≥95% | 100 µmol; 0.25 g |
| 5-[N-(2-Aminoethyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7040 | ≥97% | 100 mg; 1 g |
| 5-[N-(6-Aminohexyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7050 | ≥90% | 100 mg; 1 g |
| 3'-Azido-3'-deoxy-5'-O-methylthymidine | PY 7075 | ≥97% | 0 g DISCONTINUED; |
| (E)-5-(2-Carbomethoxyvinyl)-2'-deoxyuridine | PY 7170 | ≥97% | 1 g; |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine | PY 7180 | ≥97% | 500 mg; 1 g |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine N-Hydroxysuccinimide Ester | PY 7190 | ≥97% | 100 mg; 1 g |
| (5S,6R)-5',6'-Cyclo-5'-deoxy-5,6-dihydrothymidine | PY 7345 | ≥95% | 10 mg; 25 mg |
| 5'-O-(Dimethoxytrityl)-5-[N-(2-(trifluoroacetamido)ethyl)-3-(E)acrylamido]-2'-deoxyuridine | PY 7520 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-[N-(6-(trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7530 | ≥97% | 100 mg; 1 g |
| 1-(3,5-Di-O-(p-toluoyl)-β-D-2-deoxyribofuranosyl)-5-(2-(phthalimidooxy)ethyl)-4-(1,2,4-triazol-1-yl)-lH-pyrimidin-2-one | PY 7550 | ≥95% | 100 mg; 1 g |
| 3',5'-Di-O-(p-toluoyl)-5-(2-hydroxyethyl)-2'-deoxyuridine | PY 7560 | ≥95% | 500 mg; 1 g |
| 5-(2-Hydroxyethyl)-2'-deoxyuridine | PY 7600 | ≥95% | 25 mg; 50 mg |
| 3-(2-Cyanoethyl)thymidine | PY 7742 | ≥95% | 10 mg; 25 mg |
| 5-[3-(Trifluoroacetamido)-E-1-propenyl]-2’-deoxyuridine | PY 7754 | ≥95% | 100 mg; 1 g |
| 5-[N(2-(Trifluoroacetamido)ethyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7760 | ≥90% | 100 mg; 1 g |
| 5-[N(6-(Trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7770 | ≥95% | 100 mg; 1 g |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| 6-Methyl-3-(β-D-2-deoxyribofuranosyl)furano-[2,3-d]pyrimidin-2-one | PYA 11055 | ≥97% | 5 mg; 25 mg |
| 5-Ethynyl uridine CEP | BA 0353 | ≥90% | 100 µmol; 0.25 g |
| 2'-O-Acetyl-5'-O-benzoyl-5-methyl-3'-deoxyuridine | PY 7000 | ≥97% | 500 mg; 1 g |
| 5-[N-(2-Aminoethyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7040 | ≥97% | 100 mg; 1 g |
| 5-[N-(6-Aminohexyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7050 | ≥90% | 100 mg; 1 g |
| 5-(Furan-2-yl)-2'-deoxyuridine | PY 7053 | ≥97% | 25 mg; 100 mg |
| 1-(β-D-2-Deoxyribofuranosyl)-4-(1,2,4-triazol-1-yl)pyrimidin-2-one | PY 7055 | ≥97% | 20 mg; 100 mg |
| 5-Bromo-2'-deoxyuridine | PY 7117 | ≥97% | 10 g; 25 g |
| 5-Bromouridine | PY 7118 | ≥95% | 5 g; |
| (E)-5-(2-Carbomethoxyvinyl)-2'-deoxyuridine | PY 7170 | ≥97% | 1 g; |
| (E)-5-(2-Carbomethoxyvinyl)uridine | PY 7172 | ≥97% | 25 mg; 250 mg |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine | PY 7180 | ≥97% | 500 mg; 1 g |
| (E)-5-(2-Carboxyvinyl)uridine | PY 7185 | ≥97% | 1 g; |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine N-Hydroxysuccinimide Ester | PY 7190 | ≥97% | 100 mg; 1 g |
| S4-(2-Cyanoethyl)-4-thio-2'-deoxyuridine | PY 7212 | ≥95% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-3'-deoxyuridine | PY 7240 | ≥95% | 25 mg; 100 mg |
| 5-Methyl-3'-deoxyuridine | PY 7260 | ≥95% | 20 mg; 50 mg |
| 2'-Deoxyuridine | PY 7275 | ≥97% | 25 g; 100 g |
| 3',5'-Di-O-acetyl-5-fluoro-2'-deoxyuridine | PY 7280 | ≥95% | 100 mg; 500 mg |
| 3'-Azido-2',3'-dideoxy-5-bromouridine | PY 7286 | ≥97% | 10 mg; 50 mg |
| 3',5'-Di-O-acetyl-5-fluoro-O4-(2,4,6-trimethylphenyl)-2'-O-methyluridine | PY 7290 | ≥95% | 500 mg; 1 g |
| 3',5'-Di-O-acetyl-5-fluoro-2'-O-methyluridine | PY 7300 | ≥97% | 50 mg; 250 mg |
| 3',5'-Di-O-acetyl-5-fluoro-O4-(2,4,6-trimethylphenyl)-2'-deoxyuridine | PY 7310 | ≥97% | 20 mg; 50 mg |
| 3',5'-Di-O-benzoyl-5-fluoro-2'-O-methyluridine | PY 7320 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-fluoro-2'-O-methyluridine | PY 7420 | ≥95% | 100 mg; 500 mg |
| 5'-O-(Dimethoxytrityl)-5-iodo-2'-deoxyuridine | PY 7450 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-iodo-2'-O-methyluridine | PY 7460 | ≥97% | 50 mg; 100 mg |
| 5-Methoxymethyl-2'-deoxyuridine | PY 7465 | ≥95% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-2'-O-methyluridine | PY 7470 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-2'-O-methyluridine | PY 7480 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-deoxyuridine | PY 7490 | ≥95% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-O-methyluridine | PY 7500 | ≥95% | 25 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-[N-(2-(trifluoroacetamido)ethyl)-3-(E)acrylamido]-2'-deoxyuridine | PY 7520 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-[N-(6-(trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7530 | ≥97% | 100 mg; 1 g |
| 1-(3,5-Di-O-(p-toluoyl)-β-D-2-deoxyribofuranosyl)-5-(2-(phthalimidooxy)ethyl)-4-(1,2,4-triazol-1-yl)-lH-pyrimidin-2-one | PY 7550 | ≥95% | 100 mg; 1 g |
| 3',5'-Di-O-(p-toluoyl)-5-(2-hydroxyethyl)-2'-deoxyuridine | PY 7560 | ≥95% | 500 mg; 1 g |
| 5-Ethynyl-2'-deoxyuridine | PY 7562 | ≥97% | 25 mg; 100 mg |
| 5-Ethynyl uridine | PY 7563 | ≥97% | 10 mg; 100 mg |
| 5-Fluoro-2'-deoxyuridine | PY 7565 | ≥97% | 100 mg; 1 g |
| 5-Fluoro-2'-O-methyluridine | PY 7570 | ≥97% | 50 mg; 100 mg |
| 5-Fluoro-O4-(2,4,6-trimethylphenyl)-2'-deoxyuridine | PY 7580 | ≥97% | 25 mg; 100 mg |
| 5-Fluoro-O4-(2,4,6-trimethylphenyl)-2'-O-methyluridine | PY 7590 | ≥95% | 25 mg; 100 mg |
| 5-Hydroxy-2'-deoxyuridine | PY 7597 | ≥95% | 25 mg; 250 mg |
| 5-(2-Hydroxyethyl)-2'-deoxyuridine | PY 7600 | ≥95% | 25 mg; 50 mg |
| 5-Acetoxymethyl-2'-deoxyuridine | PY 7604 | ≥97% | 25 mg; 100 mg |
| 5-Hydroxymethyl-2'-deoxyuridine | PY 7605 | ≥95% | 25 mg; 250 mg |
| 2'-Fluoro-5'-iodo deoxyuridine | PY 7612 | ≥95% | 100 mg; |
| 5-Iodo-2'-deoxyuridine | PY 7615 | ≥97% | 10 g; 25 g |
| 5-Iodo-2'-O-methyluridine | PY 7630 | ≥97% | 100 mg; 1 g |
| 5-Iodouridine | PY 7632 | ≥95% | 5 g; 25 g |
| 5-Methyl-2'-O-methyluridine | PY 7650 | ≥97% | 100 mg; 1 g |
| 5-(1-Propynyl)-2'-O-methyluridine | PY 7670 | ≥97% | 10 mg; 25 mg |
| 2'-O-Methyluridine | PY 7690 | ≥97% | 5 g; |
| 3-Methyluridine | PY 7694 | ≥97% | 25 mg; 100 mg |
| 5-Methyluridine | PY 7695 | ≥97% | 200 mg; 1 g |
| 5-(1-Propynyl)-2'-deoxyuridine | PY 7710 | ≥97% | 100 mg; 1 g |
| 5-(Propargyloxy)-2'-deoxyuridine | PY 7712 | ≥95% | 10 mg; 100 mg |
| Zebularine | PY 7715 | ≥97% | 10 mg; 25 mg |
| 3',5'-O-(1,1,3,3-Tetraisopropyl-1,3-disiloxanediyl)-2'-deoxyuridine | PY 7720 | ≥90% | 500 mg; 1 g |
| 2-Thiouridine | PY 7724 | ≥97% | 25 mg; 100 mg |
| 5'-O-(p-Toluenesulfonyl)-2'-deoxyuridine | PY 7730 | ≥97% | 1 g; 5 g |
| 5-[3-(Trifluoroacetamido)-E-1-propenyl]-2’-deoxyuridine | PY 7754 | ≥95% | 100 mg; 1 g |
| 5-[3-(Trifluoroacetamido)-1-(E)-propenyl]uridine | PY 7758 | ≥97% | 100 mg; 1 g |
| 5-[N(2-(Trifluoroacetamido)ethyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7760 | ≥90% | 100 mg; 1 g |
| 5-[N(6-(Trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7770 | ≥95% | 100 mg; 1 g |
| 5-[N-(6-(Trifluoracetamido)hexyl)-(E)-acrylamido]uridine | PY 7775 | ≥97% | 100 mg; 1 g |
| Uridine | PY 7780 | ≥97% | 100 g; 500 g |
| 2'3'-O-Isopropylidene uridine | PY 7781 | ≥97% | 5 g; 25 g |
| 5-Hydroxymethyl uridine | PY 7782 | ≥97% | 50 mg; 100 mg |
| 5-Methoxyuridine | PY 7783 | ≥97% | 10 mg; 50 mg |
| 6-Aza-2'-deoxyuridine | PYA 11057 | ≥95% | 50 mg; 100 mg |
" data-original="http://genvivo.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="艾美捷科技代理Berry & Associates全系列修饰核苷酸"> 艾美捷科技代理Berry & Associates全系列修饰核苷酸

Anogen-Yes Biotech Laboratories Ltd. 创建于1989年, 位于加拿大多伦多近郊的著名高科技城市密西沙加市。Anogen是加拿大逸士生物技术研究有限公司在国际上的市场经销部门。Anogen-Yes Biotech Laboratories Ltd.研发和生产各种新颖抗体及有关产品,应用广泛的技术平台设计和开发各种单克隆抗体、多克隆抗体、基因工程/人源化抗体、免疫检验用配对抗体、免疫球蛋白、活性多肽、酶联免疫试剂盒[ELISA]、斑点酶联免疫试剂盒[Elispots]和基因重组蛋白质等等。 这些产品主要用于生命科学研究和各种疾病的诊断和防治,包括炎症和自身免疫性疾病、心血管病和癌症等。
Anogen is the trade name of Yes Biotech Laboratories Ltd., a Canadian biopharmaceutical company based in Mississauga, Ontario. Founded in 1989, Anogen-Yes Biotech specializes in developing and manufacturing monoclonal antibodies, recombinant proteins, synthetic bioactive peptides, and Enzyme linked immunosorbent assay (ELISA) kits for research as well as diagnostic and therapeutic use.[1] It is also committed to seeking medical treatment of cancer, autoimmune, inflammatory and cardiovascular diseases by developing antibody-based biopharmaceuticals.
Anogen的主要产品包括:
Monoclonal Antibodies
Polyclonal Antibodies
Matched Antibody Pairs
ELISA Kits
按照研究领域细分:
Inflammatory & Growth Factors
Cell Biology & Molecular Biology
Immunoassay Reagents
Infection & Toxin
Coagulation Factors
Hormone
Neurological Disorder
Tumor Research
| 品名 | 货号 | 规格 |
| mAb anti-Human TNF-α, CH8810 | MO-C40003A | 0.1 mg |
| mAb anti-Human TNF-α, CH8820, Capture | MO-C40003B | 0.1 mg |
| mAb anti-Human TNF-α, C2H9 | MO-C40003D | 0.1 mg |
| mAb anti-Human TNF-α, B1E4, Detector | MO-C40003E | 0.1 mg |
| mAb anti-Human TNF-α, C2A7 | MO-C40003F | 0.1 mg |
| mAb anti-Human TNF-α, C5G7 | MO-C40003G | 0.1 mg |
| mAb anti-Human TNF-α, C4C7 | MO-C40003H | 0.1 mg |
| mAb anti-Human IFN-γ, 315 | MO-C40004D | 0.1 mg |
| mAb anti-Human IFN-γ, 165 | MO-C40004E | 0.1 mg |
| mAb anti-Human IFN-γ, 23 | MO-C40004F | 0.1 mg |
| mAb anti-Human CCR1, 293 | MO-C40005A | 0.1 mg |
| mAb anti-Human TGF-β, TB21 | MO-C40009A | 0.1 mg |
| mAb anti-Human TGF-β, 2C5 | MO-C40009B | 0.1 mg |
| mAb anti-Human TGF-β, 2C6 | MO-C40009D | 0.1 mg |
| mAb anti-Human TGF-β, 2E6 | MO-C40009E | 0.1 mg |
| mAb anti-Human TGF-β, 8C4 | MO-C40009F | 0.1 mg |
| mAb anti-Human IL-8, I8-S2, Capture | MO-C40017A | 0.1 mg |
| mAb anti-Human IL-8, I8-60, Detector | MO-C40017D | 0.1 mg |
| mAb anti-Human IL-8, I8-61 | MO-C40017E | 0.1 mg |
| mAb anti-Human IL-8, 257 | MO-C40017F | 0.1 mg |
| mAb anti-Human IL-8, 807 | MO-C40017G | 0.1 mg |
| mAb anti-Human MCP-1, S8 | MO-C40021A | 0.1 mg |
| mAb anti-Human MCP-1, S14, Capture | MO-C40021B | 0.1 mg |
| mAb anti-Human MCP-1, S101, Detector | MO-C40021D | 0.1 mg |
| mAb anti-Human MCP-1, 9G10 | MO-C40021E | 0.1 mg |
| mAb anti-Human MCP-1, S382 | MO-C40021F | 0.1 mg |
| mAb anti-Human SAA, 115, Capture | MO-C40028A | 0.1 mg |
| mAb anti-Human SAA, 513 | MO-C40028D | 0.1 mg |
| mAb anti-Human SAA, 607, Detector | MO-C40028E | 0.1 mg |
| mAb anti-Human SAA, 291 | MO-C40028G | 0.1 mg |
| mAb anti-Human SAA, 504 | MO-C40028H | 0.1 mg |
| mAb anti-Human SAA, 585 | MO-C40028J | 0.1 mg |
| mAb anti-Human SAA, 426 | MO-C40028K | 0.1 mg |
| mAb anti-Human SAA, 38 | MO-C40028L | 0.1 mg |
| mAb anti-Human SAA, 132 | MO-C40028M | 0.1 mg |
| mAb anti-Human SAA, S3 | MO-C40028N | 0.1 mg |
| mAb anti-Human IL-1β, S1H12 | MO-C40029A | 0.1 mg |
| mAb anti-Human IL-1β, S1B7 | MO-C40029B | 0.1 mg |
| mAb anti-Human IL-1β, S3F12 | MO-C40029G | 0.1 mg |
| mAb anti-Human IL-1β, 464 | MO-C40029H | 0.1 mg |
| mAb anti-Human IL-2, 5A8, | MO-C40032A | 0.1 mg |
| mAb anti-Human IL-2, 9F9, | MO-C40032B | 0.1 mg |
| mAb anti-Human IL-2, 10C4 | MO-C40032C | 0.1 mg |
| mAb anti-Human IL-2, 8C2 | MO-C40032D | 0.1 mg |
| mAb anti-Human IL-2, 6F11 | MO-C40032E | 0.1 mg |
| mAb anti-Human IL-2, 6B1 | MO-C40032F | 0.1 mg |
| mAb anti-Human EGF, S-21 | MO-C40044A | 0.1 mg |
| mAb anti-Human EGF, S-120 | MO-C40044B | 0.1 mg |
| mAb anti-Human EGF, S-134, Capture | MO-C40044D | 0.1 mg |
| mAb anti-Human EGF, S-145 | MO-C40044E | 0.1 mg |
| mAb anti-Human EGF, S-146, Detector | MO-C40044F | 0.1 mg |
| mAb anti-Human EGF, S-147 | MO-C40044G | 0.1 mg |
| mAb anti-Human EGF, S-177 | MO-C40044H | 0.1 mg |
| mAb anti-Human G-CSFR, S-1252 | MO-C40045A | 0.1 mg |
| mAb anti-Human G-CSFR, S-1268 | MO-C40045B | 0.1 mg |
| mAb anti-Human G-CSFR, S-1284 | MO-C40045D | 0.1 mg |
| mAb anti-Human G-CSFR, S-1374 | MO-C40045E | 0.1 mg |
| mAb anti-Human G-CSFR, S-425 | MO-C40045F | 0.1 mg |
| mAb anti-Human G-CSFR, S-1390 | MO-C40045G | 0.1 mg |
| mAb anti-Human bFGF, F-343 | MO-C40046A | 0.1 mg |
| mAb anti-Human bFGF, F-74 | MO-C40046B | 0.1 mg |
| mAb anti-Human bFGF, F-474 | MO-C40046F | 0.1 mg |
| mAb anti-Human bFGF, F-3 | MO-C40046H | 0.1 mg |
| mAb anti-Human EPO, 85 | MO-C40047A | 0.1 mg |
| mAb anti-Human M-CSF, 116 | MO-C40048A | 0.1 mg |
| mAb anti-Human M-CSF, 692 | MO-C40048B | 0.1 mg |
| mAb anti-Human M-CSF, 21 | MO-C40048D | 0.1 mg |
| mAb anti-Human MIP-1α, 116 | MO-C40051A | 0.1 mg |
| mAb anti-Human MIP-1α, 125 | MO-C40051D | 0.1 mg |
| mAb anti-Human MIP-1α, 548 | MO-C40051F | 0.1 mg |
| mAb anti-Human MIP-1α, 199 | MO-C40051G | 0.1 mg |
| mAb anti-Human MIP-1α, 400 | MO-C40051L | 0.1 mg |
| mAb anti-Human MIP-1α, 103 | MO-C40051M | 0.1 mg |
| mAb anti-Human MIP-1α, 376 | MO-C40051N | 0.1 mg |
| mAb anti-Human MIP-1α, 426 | MO-C40051P | 0.1 mg |
| mAb anti-Human MCP-3, 113, Detector | MO-C40088A | 0.1 mg |
| mAb anti-Human MCP-3, 343 | MO-C40088B | 0.1 mg |
| mAb anti-Human MCP-3, 490 | MO-C40088D | 0.1 mg |
| mAb anti-Human MCP-3, 768 | MO-C40088E | 0.1 mg |
| mAb anti-Human MCP-3, 1057 | MO-C40088F | 0.1 mg |
| mAb anti-Human MCP-3, 542, Capture | MO-C40088G | 0.1 mg |
| mAb anti-Human MCP-3, 1015 | MO-C40088H | 0.1 mg |
| mAb anti-Human IL-16, 59 | MO-C40089G | 0.1 mg |
| mAb anti-Human IL-16, 210 | MO-C40089H | 0.1 mg |
| mAb anti-Human IL-16, 323, Detector | MO-C40089J | 0.1 mg |
| mAb anti-Human IL-16, 398, Capture | MO-C40089K | 0.1 mg |
| mAb anti-Human IL-16, 568 | MO-C40089M | 0.1 mg |
| mAb anti-Human IL-16, 572 | MO-C40089N | 0.1 mg |
| mAb anti-Human GM-CSF, 29 | MO-C40090A | 0.1 mg |
| mAb anti-Human GM-CSF, 59, Capture | MO-C40090B | 0.1 mg |
| mAb anti-Human GM-CSF, 429, Detector | MO-C40090D | 0.1 mg |
| mAb anti-Human GM-CSF, 204 | MO-C40090E | 0.1 mg |
| mAb anti-Human GM-CSF, 489 | MO-C40090F | 0.1 mg |
| mAb anti-Human GM-CSF, 120 | MO-C40090G | 0.1 mg |
| mAb anti-Human GM-CSF, 26 | MO-C40090H | 0.1 mg |
| mAb anti-Human GM-CSF, 174 | MO-C40090K | 0.1 mg |
| mAb anti-Human GM-CSF, S333 | MO-C40090L | 0.1 mg |
| mAb anti-Human IL-6, 2E10 | MO-C40091B | 0.1 mg |
| mAb anti-Human IL-6, 8E10 | MO-C40091C | 0.1 mg |
| mAb anti-Human IL-6, 5G8 | MO-C40091D | 0.1 mg |
| mAb anti-Human IL-6, 1B6 | MO-C40091E | 0.1 mg |
| mAb anti-Human IL-6, 1E3 | MO-C40091F | 0.1 mg |
| mAb anti-Human IL-6, 6D7 | MO-C40091G | 0.1 mg |
| mAb anti-Human IL-6, 9D8 | MO-C40091H | 0.1 mg |
| mAb anti-Human IL-10, 4H2 | MO-C40092A | 0.1 mg |
| mAb anti-Human IL-10, 6D2 | MO-C40092B | 0.1 mg |
| mAb anti Human IL-17A clone 4C1, Capture | MO-C40093A | 0.1mg |
| mAb anti Human IL-17A clone 2F3 | MO-C40093B | 0.1mg |
| mAb anti Human IL-17A clone 8H7 | MO-C40093C | 0.1mg |
| mAb anti Human IL-17A clone 5B4 | MO-C40093D | 0.1mg |
| mAb anti Human IL-17A clone 1E2 | MO-C40093E | 0.1mg |
| mAb anti Human IL-17A clone 2D11 | MO-C40093H | 0.1mg |
| mAb anti Human IL-17A clone 3C1 | MO-C40093I | 0.1mg |
| mAb anti Human IL-17A clone 3H11, Detector | MO-C40093K | 0.1mg |
| mAb anti Human IL-17A clone 5A9 | MO-C40093M | 0.1mg |
| mAb anti Human IL-17A clone 6F12 | MO-C40093O | 0.1mg |
| mAb anti Human IL-17A clone 7F10 | MO-C40093S | 0.1mg |
| mAb anti Human IL-17A clone 10F9 | MO-C40093W | 0.1mg |
| mAb anti Human IL-18 clone 2A10, Capture | MO-C40094A | 0.1mg |
| mAb anti Human IL-18 clone 10H4, Detector | MO-C40094B | 0.1mg |
| mAb anti human IL-18 clone 10H4, Tracer (Biotin Labeled) | MO-C40094TB | 0.1 mL |
| mAb anti Human IL-15 clone 5E8, Capture | MO-C40095A | 0.1mg |
| mAb anti Human IL-15 clone B1H6, Detector | MO-C40095B | 0.1mg |
| mAb anti-human LIF, Clone 2C6 | MO-C40096A | 0.1mg |
| mAb anti-human LIF, Clone 3F4 | MO-C40096B | 0.1mg |
| mAb anti-human LIF, Clone 8B10 | MO-C40096C | 0.1mg |
| mAb anti-DYKDDDDK (Flag) Tag, Flag.10F4 | MO-H40001B | 0.1 mg |
| mAb anti-GAPDH, H8 | MO-H40002A | 0.1 mg |
| mAb anti-HA Tag, HA52 | MO-H40004A | 0.1 mg |
| mAb anti-His Tag, 10A12 | MO-H40005B | 0.1 mg |
| mAb anti-Myc Tag, MycA7 | MO-H40006A | 0.1 mg |
| mAb anti-V5 Tag, V531 | MO-H40007A | 0.1 mg |
| mAb anti-HIV-1 P24 (Core Protein), 473, Detector | MO-I40002A | 0.1 mg |
| mAb anti-HIV-1 P24 (Core Protein), 163 | MO-I40002C | 0.1 mg |
| mAb anti-HIV-1 P24 (Core Protein), 340, Capture | MO-I40002D2 | 0.1 mg |
| mAb anti-HIV-1 P24 (Core Protein), 587, 0.1 mg | MO-I40002E | 0.1 mg |
| mAb anti-HIV-1 P24 (Core Protein), 425 | MO-I40002I | 0.1 mg |
| mAb anti-HIV-1 P24 (Core Protein), 1027 | MO-I40002J | 0.1 mg |
| mAb anti-HIV-1 P24 (Core Protein), 287 | MO-I40002N | 0.1 mg |
| mAb anti-HIV-1 P24 (Core Protein), 161 | MO-I40002P | 0.1 mg |
| mAb anti-HBsAg, RM-1 | MO-I40013A | 0.1 mg |
| mAb anti-HCV Core Protein, A1/3D1 | MO-I40015A | 0.1 mg |
| mAb anti-HCV Core Protein, B2 | MO-I40015B | 0.1 mg |
| mAb anti-HCV Core Protein, C3 | MO-I40015E | 0.1 mg |
| mAb anti-HCV NS-4, 7B7/5G9 | MO-I40016B | 0.1 mg |
| mAb anti-HCV NS-4, 5D4/10E7 | MO-I40016D | 0.1 mg |
| mAb anti-HCV NS-4, 7E11 | MO-I40016F | 0.1 mg |
| mAb anti-HCV NS-4, 202 | MO-I40016J | 0.1 mg |
| mAb anti-HCV NS-4, 101 | MO-I40016K | 0.1 mg |
| mAb anti-HCV NS-4, 174 | MO-I40016L | 0.1 mg |
| mAb anti-HCV NS-4, 497 | MO-I40016M | 0.1 mg |
| mAb anti-HCV NS-3, 70-13 | MO-I40018A | 0.1 mg |
| mAb anti-HCV NS-3, 1-5 | MO-I40018B | 0.1 mg |
| mAb anti-HCV NS-3, 12-15 | MO-I40018D | 0.1 mg |
| mAb anti-HCV NS-3, 5-11 | MO-I40018E | 0.1 mg |
| mAb anti-HCV NS-3, 24-8 | MO-I40018F | 0.1 mg |
| mAb anti-HCV NS-3, 20-8 | MO-I40018G | 0.1 mg |
| mAb anti-HCV NS-3, 113 | MO-I40018H | 0.1 mg |
| mAb anti-HCV NS-3, 281 | MO-I40018J | 0.1 mg |
| mAb anti-HCV NS-3, 806 | MO-I40018K | 0.1 mg |
| mAb anti-HCV NS-3, 5 | MO-I40018L | 0.1 mg |
| mAb anti-HCV NS-3, 328 | MO-I40018M | 0.1 mg |
| mAb anti-HCV NS-3, 251 | MO-I40018N | 0.1 mg |
| mAb anti-HCV NS-3, 242 | MO-I40018P | 0.1 mg |
| mAb anti-HCV NS-3, 133 | MO-I40018Q | 0.1 mg |
| mAb anti-HEV, S-13 | MO-I40019B | 0.1 mg |
| mAb anti-HEV, 4H5 | MO-I40019C | 0.1 mg |
| mAb anti-HEV, 2H6 | MO-I40019D | 0.1 mg |
| mAb anti-HEV, 2H2 | MO-I40019E | 0.1 mg |
| mAb anti-HEV, 1B6 | MO-I40019F | 0.1 mg |
| mAb anti-HEV, 5H4 | MO-I40019G | 0.1 mg |
| mAb anti-HP CagA, 10E9, | MO-I40020A | 0.1 mg |
| mAb anti-HP CagA, 5H10 | MO-I40020B | 0.1 mg |
| mAb anti-HP CagA, 5C6 | MO-I40020C | 0.1 mg |
| mAb anti-HP CagA, 3C10, | MO-I40020D | 0.1 mg |
| mAb anti-HP CagA, 3C1 | MO-I40020E | 0.1 mg |
| mAb anti-TB 38KD Antigen, D2G2 | MO-I40021A | 0.1 mg |
| mAb anti-TB 38KD Antigen, C12H11 | MO-I40021B | 0.1 mg |
| mAb anti-TB 38KD Antigen, C11B10 | MO-I40021C | 0.1 mg |
| mAb anti-TB 38KD Antigen, B12F8 | MO-I40021D | 0.1 mg |
| mAb anti-TB 38KD Antigen, A11D2 | MO-I40021E | 0.1 mg |
| mAb anti-TB 38KD Antigen, A2H8 | MO-I40021F | 0.1 mg |
| mAb anti-Human CD3, JXT3 | MO-L40001A | 0.1 mg |
| Rat anti-Mouse CD4, JXYT4 | MO-L40026 | 0.1 mg |
| Rat anti-Mouse CD8, JXYT8 | MO-L40027 | 0.1 mg |
| mAb anti-Human CD11α, A11 | MO-L40028 | 0.1 mg |
| mAb anti-Human HLA-ABC, LY5.1 | MO-L40033 | 0.1 mg |
| mAb anti-Human CD71 Transferrin Receptor, CY-TFR | MO-L40042 | 0.1 mg |
| mAb anti-Human PD-1 / CD279, 1C4 | MO-L40043A | 0.1 mg |
| mAb anti-Human PD-1 / CD279, 7C9, Capture | MO-L40043B | 0.1 mg |
| mAb anti-Human PD-1 / CD279, 9E11 | MO-L40043E | 0.1 mg |
| mAb anti-Human PD-1 / CD279, 9B4 | MO-L40043F | 0.1 mg |
| mAb anti-Human PD-1 / CD279, B1C4 | MO-L40043G | 0.1 mg |
| mAb anti-Human PD-1 / CD279, 7G12, Detector | MO-L40043L | 0.1 mg |
| mAb anti-Human PD-1 / CD279, 2H7 | MO-L40043M | 0.1 mg |
| mAb anti Human PD-L1, clone 6A5 | MO-L40044E | 0.1 mg |
| mAb anti Human PD-L1 clone 8C12 | MO-L40044F | 0.1 mg |
| mAb anti Human PD-L1 clone 12B4, Detector | MO-L40044I | 0.1 mg |
| mAb anti Human PD-L1 clone 11D11 | MO-L40044M | 0.1 mg |
| mAb anti Human PD-L1 clone 15G3, Capture | MO-L40044N | 0.1 mg |
| mAb anti Human PD-L1 clone 12D9 | MO-L40044O | 0.1 mg |
| mAb anti Human PD-L1 clone 15F2 | MO-L40044R | 0.1 mg |
| mAb anti Human PD-L1, clone 10B12 | MO-L40044S | 0.1 mg |
| mAb anti Human CD47, clone 1G10 | MO-L40045A | 0.1 mg |
| mAb anti Human CD47, clone 8H7 | MO-L40045B | 0.1 mg |
| mAb anti Human CD47, clone 9F10 | MO-L40045C | 0.1 mg |
| mAb anti Human CD44, clone 2G7 | MO-L40046A | 0.1 mg |
| mAb anti Human CD44, clone 3C7 | MO-L40046B | 0.1 mg |
| mAb anti-hCG-α, CH5 | MO-M40010A | 0.1 mg |
| mAb anti-hCG-α, CH7 | MO-M40010B | 0.1 mg |
| mAb anti-TRICHOSANTHIN (TCST), TCST-1, 0.1 mg | MO-M40011A | 0.1 mg |
| mAb anti-hGH, YC6, Capture | MO-M40012A | 0.1 mg |
| mAb anti-Human Ig Kappa Light Chain, YCK1 | MO-M40020 | 0.1 mg |
| mAb anti-Human B2MG, D6E4 | MO-M40021B | 0.1 mg |
| mAb anti-Human B2MG, D2E9, Capture | MO-M40021C | 0.1 mg |
| mAb anti-Human B2MG, D6D1 | MO-M40021D | 0.1 mg |
| mAb anti-Human B2MG, D2A10 | MO-M40021E | 0.1 mg |
| mAb anti-Human B2MG, D3A2, Detector | MO-M40021F | 0.1 mg |
| mAb anti-human CRP, 63F4, Capture | MO-M40023A | 0.1 mg |
| mAb anti-human CRP, 67A1 | MO-M40023B | 0.1 mg |
| mAb anti-human CRP, N1G1 | MO-M40023D | 0.1 mg |
| mAb anti-human CRP, S5G1 | MO-M40023E | 0.1 mg |
| mAb Rat anti-Aflatoxin, 1C6, 0.1 mg | MO-M40025A | 0.1 mg |
| mAb Rat anti-Aflatoxin, 1E6, 0.1 mg | MO-M40025B | 0.1 mg |
| mAb Rat anti-Aflatoxin, 2E4 | MO-M40025D | 0.1 mg |
| mAb anti-Human Albumin, S4D6 | MO-M40036 | 0.1 mg |
| mAb anti-Human Factor IX, F9-1, .01 mg | MO-M40037 | 0.1 mg |
| mAb anti-Human Protein C, HLW-C, 0.1 mg | MO-M40038 | 0.1 mg |
| mAb anti-Human Factor X, F10-1, 0.1 mg | MO-M40039 | 0.1 mg |
| mAb anti-Human GP IIb/IIIa, 237, 0.1 mg | MO-M40040A | 0.1 mg |
| mAb anti-Human GP IIb/IIIa, 474, 0.1 mg | MO-M40040B | 0.1 mg |
| mAb anti-Human GP IIb/IIIa, Y8 | MO-M40040D | 0.1 mg |
| mAb anti-Human GP IIb/IIIa, 700 | MO-M40040E | 0.1 mg |
| mAb anti-Human GP IIb/IIIa, 585 | MO-M40040F | 0.1 mg |
| mAb anti-Human GP IIb/IIIa, 8 | MO-M40040H | 0.1 mg |
| mAb anti-Human GP IIb/IIIa, 291 | MO-M40040J | 0.1 mg |
| mAb anti-Human GP IIb/IIIa, 262 | MO-M40040N | 0.1 mg |
| mAb anti-Human GP IIb/IIIa, 71 | MO-M40040Q | 0.1 mg |
| mAb anti-Human GP IIb/IIIa, 128 | MO-M40040S | 0.1 mg |
| mAb anti-Staphylococcal Enterotoxin B [SEB], 0.1 mg | MO-M40041 | 0.1 mg |
| mAb anti-Human PTP1-C, PTY6 | MO-M40043A | 0.1 mg |
| mAb anti-Human PTP1-C, PTY11 | MO-M40043B | 0.1 mg |
| mAb anti-Human PTP1-C, PTY15 | MO-M40043D | 0.1 mg |
| mAb anti-Human PTP1-C, PTY10 | MO-M40043E | 0.1 mg |
| mAb anti-Human PTP1-C, PTY13 | MO-M40043F | 0.1 mg |
| mAb anti-human TSH, TSH-2, Detector | MO-M40046A | 0.1 mg |
| mAb anti-human TSH, TSH-1, Capture | MO-M40046B | 0.1 mg |
| mAb anti-Human Prolactin, PRL-1, Capture | MO-M40047B | 0.5 mg |
| mAb anti-Human LH, LH-1, Capture | MO-M40048B | 0.5 mg |
| mAb anti-hCG, HCG-1, Capture | MO-M40049B | 0.5 mg |
| mAb anti-Human FSH, FSH-1, Capture | MO-M40050B | 0.5 mg |
| mAb anti-Human Raf-1, 410 | MO-M40091E | 0.5 mg |
| mAb anti-Human Raf-1, 540 | MO-M40091G | 0.5 mg |
| mAb anti-Human Raf-1, 863 | MO-M40091J | 0.5 mg |
| mAb anti-Human Raf-1, 163 | MO-M40091M | 0.5 mg |
| mAb anti-Human NSE, 145 | MO-M40092A | 0.5 mg |
| mAb anti-Human NSE, 1G6 | MO-M40092B | 0.5 mg |
| mAb anti-Human NSE, 171 | MO-M40092C | 0.5 mg |
| mAb anti-Amyloid β Peptide 42, CA9 3B3 | MO-M40093A | 0.1 mg |
| mAb anti-Amyloid β Peptide 42, CA9 10C11, Detector | MO-M40093B | 0.5 mg |
| mAb anti-Amyloid β Peptide 42, CA9 3F8 | MO-M40093D | 0.5 mg |
| mAb anti-Amyloid β Peptide N-terminal, NT 3F5 | MO-M40094A | 0.5 mg |
| mAb anti-Amyloid β Peptide N-terminal, NT 1H3 | MO-M40094B | 0.5 mg |
| mAb anti-Amyloid β Peptide N-terminal, NT 6C8 | MO-M40094C | 0.5 mg |
| mAb anti-Amyloid β Peptide N-terminal, NT 5B8, Capture | MO-M40094D | 0.5 mg |
| mAb anti-Amyloid β Peptide N-terminal, NT 4A2 | MO-M40094E | 0.5 mg |
| mAb anti-Amyloid β Peptide N-terminal, NT 7H7 | MO-M40094F | 0.5 mg |
| mAb anti-Amyloid β Peptide N-terminal, NT 5A4 | MO-M40094G | 0.5 mg |
| mAb anti-Amyloid β Peptide N-terminal, NT 4B7 | MO-M40094H | 0.5 mg |
| mAb anti-Amyloid β Peptide N-terminal, NT 7G10 | MO-M40094I | 0.5 mg |
| mAb anti-Amyloid β Peptide N-terminal, NT 1F10 | MO-M40094J | 0.5 mg |
| mAb anti-Amyloid β Peptide 40, CV9 7B10, Detector | MO-M40095A | 0.1 mg |
| mAb anti-Amyloid β Peptide 40, CV9 8B2 | MO-M40095B | 0.1 mg |
| mAb anti-Amyloid β Peptide 40, 4B1 | MO-M40095C | 0.1 mg |
| mAb anti-Human α1-antitrypsin, 5G5 | MO-M40096A | 0.1 mg |
| mAb anti-Human α1-antitrypsin, 9F2 | MO-M40096B | 0.1 mg |
| mAb anti-Human α-Synuclein, 4H11 | MO-M40097A | 0.1 mg |
| mAb anti-Human α-Synuclein, 4C1 | MO-M40097B | 0.1 mg |
| mAb anti-Human α-Synuclein, 4B4 | MO-M40097C | 0.1 mg |
| mAb anti-Human α-Synuclein, 8F12 | MO-M40097D | 0.1 mg |
| mAb anti-Human α-Synuclein, 9A9 | MO-M40097E | 0.1 mg |
| mAb anti-Human α1-antichymotrypsin, 3E11 | MO-M40098A | 0.1 mg |
| mAb anti-Human α1-antichymotrypsin, B2B3 | MO-M40098B | 0.1 mg |
| mAb anti-Human α1-antichymotrypsin, B4H12 | MO-M40098C | 0.1 mg |
| mAb anti-Human α1-antichymotrypsin, B5B11 | MO-M40098D | 0.1 mg |
| mAb anti-Human α1-antichymotrypsin, B7B10 | MO-M40098E | 0.1 mg |
| mAb anti-Human α1-antichymotrypsin, B7H2 | MO-M40098F | 0.1 mg |
| mAb anti-Thr181 Phosphorylated Tau, 1A4 | MO-M40099A | 0.1 mg |
| mAb anti-Thr181 Phosphorylated Tau, 7G9 | MO-M40099B | 0.1 mg |
| mAb anti-Thr181 Phosphorylated Tau, 9B4 | MO-M40099C | 0.1 mg |
| mAb anti-Thr181 Phosphorylated Tau, 2A4 | MO-M40099D | 0.1 mg |
| mAb anti-human Thr212 Thr217 double phosphorylated Tau, 8E1 | MO-M40100A | 0.1 mg |
| mAb anti-human Thr212 Thr217 double phosphorylated Tau, 1G8 | MO-M40100B | 0.1 mg |
| mAb anti-human Thr212 Thr217 double phosphorylated Tau, 4C1 | MO-M40100C | 0.1 mg |
| mAb anti-human Thr212 Thr217 double phosphorylated Tau, 3B12 | MO-M40100D | 0.1 mg |
| mAb anti-human Thr212 Thr217 double phosphorylated Tau, 4H1 | MO-M40100E | 0.1 mg |
| mAb anti-human Thr212 Thr217 double phosphorylated Tau, 4H11 | MO-M40100F | 0.1 mg |
| mAb anti-human Thr212 Thr217 double phosphorylated Tau, 5C11 | MO-M40100G | 0.1 mg |
| mAb anti-human Thr212 Thr217 double phosphorylated Tau, 10G9 | MO-M40100H | 0.1 mg |
| mAb anti-LCRMP4, 5H5 | MO-M40101A | / |
| mAb anti-LCRMP4, 2H7 | MO-M40101B | / |
| mAb anti-LCRMP4 , 7E1 | MO-M40101C | / |
| mAb anti-Human Phospho-STAT5b [p-Y699], A4B9 | MO-P40001A | 0.1 mg |
| mAb anti-Human Phospho-STAT5b [p-Y699], A2H6 | MO-P40001B | 0.1 mg |
| mAb anti-Human Phospho-ELK-1 [p-S383], B4A12 | MO-P40002A | 0.1 mg |
| mAb anti-Human Phospho-ELK-1 [p-S383], D7H2 | MO-P40002B | 0.1 mg |
| mAb anti-Human Phospho-CREB [p-S133], A3A4 | MO-P40003A | 0.1 mg |
| mAb anti-Human Phospho-CREB [p-S133], B1C4 | MO-P40003B | 0.1 mg |
| mAb anti-Human FPRL-1 C-terminal, C4F9 | MO-P40006A | 0.1 mg |
| mAb anti-Human FPRL-1 C-terminal, B4D9B10 | MO-P40006B | 0.1 mg |
| mAb anti-Human FPRL-1 2nd extracellular loop, 3D7 | MO-P40007A | 0.1 mg |
| mAb anti-Human FPRL-1 2nd extracellular loop, B7H10 | MO-P40007B | 0.1 mg |
| mAb anti-Human Lung Carcinoma, CHALU2 | MO-T40005B | 0.1 mg |
| mAb anti-Human Lung Carcinoma, 3504 | MO-T40005C | 0.1 mg |
| mAb anti-Human Hepatocellular Carcinoma, CHALV1 | MO-T40006A | 0.1 mg |
| mAb anti-Human AFP, AFP-Y2, Detector | MO-T40007A | 0.1 mg |
| mAb anti-Human AFP, AFP-Y1, Capture | MO-T40007B | 0.1 mg |
| mAb anti-Human BPH, YBPH-1 | MO-T40008A | 0.1 mg |
| mAb anti-Human BPH, YBPH-2 | MO-T40008B | 0.1 mg |
| mAb anti-Human PML, B3E9 | MO-T40010A | 0.1 mg |
| mAb anti-Human PML, B4C8 | MO-T40010B | 0.1 mg |
| mAb anti-CA 125, 110 | MO-T40012A | 0.1 mg |
| mAb anti-CA 125, 76 | MO-T40012B | 0.1 mg |
| mAb anti-CA 125, 23 | MO-T40012C | 0.1 mg |
| mAb anti-CA 125, 15 | MO-T40012D | 0.1 mg |
| mAb anti-CA 125 | MO-T40012E | 0.1 mg |
| mAb anti-CA50, 93 | MO-T40014A | 0.1 mg |
| mAb anti-CA50, 826 | MO-T40014B | 0.1 mg |
| mAb anti- human carbohydrate antigen 19-9 (CA 19-9) ,8E2 (Free Sample Available) | MO-T40015A | 0.1 mg |
| mAb anti- human carbohydrate antigen 19-9 (CA 19-9) ,9B2 (Free Sample Available) | MO-T40015B | 0.1 mg |
| mAb anti- human carbohydrate antigen 19-9 (CA 19-9) ,1A5 (Free Sample Available) | MO-T40015C | 0.1 mg |
| mAb anti- human carbohydrate antigen 19-9 (CA 19-9) ,4E11 (Free Sample Available) | MO-T40015D | 0.1 mg |
| mAb anti- human carbohydrate antigen 19-9 (CA 19-9) ,9E1 (Free Sample Available) | MO-T40015E | 0.1 mg |
| mAb anti- human carbohydrate antigen 19-9 (CA 19-9) ,7C4 (Free Sample Available) | MO-T40015F | 0.1 mg |
| mAb anti- human carbohydrate antigen 19-9 (CA 19-9) ,7E6 (Free Sample Available) | MO-T40015G | 0.1 mg |
| mAb anti-Human Colorectal Carcinoma, Y94 | MO-T40022 | 0.1 mg |
| mAb anti-Human Colorectal Carcinoma/CD3, BS-1 | MO-T40035 | 0.1 mg |
| mAb anti-Human CEA, CEA-Y2, Detector | MO-T40051A | 0.1 mg |
| mAb anti-Human CEA, CEA-Y1, Capture | MO-T40051B | 0.1 mg |
| mAb anti-Human Free PSA, 103, Detector | MO-T40052A | 0.1 mg |
| mAb anti-Human Free PSA, 108, Capture | MO-T40052B | 0.1 mg |
| mAb anti-Human PSA, CHYH1, Capture | MO-T40081A | 0.1 mg |
| mAb anti-Human PSA, CHYH2, Dectector | MO-T40081B | 0.1 mg |
| mAb anti-Human PMA, YPMA-1 | MO-T40083A | 0.1 mg |
| mAb anti-Human PMA, YPMA-2 | MO-T40083B | 0.1 mg |
| mAb anti-Human PSP, YPSP-1 | MO-T40085A | 0.1 mg |
| mAb anti-Human PSP, YPSP-2 | MO-T40085B | 0.1 mg |
| mAb anti-Human PSP, YPSP-3 | MO-T40085C | 0.1 mg |
| mAb anti-Human PSP, YPSP-4 | MO-T40085D | 0.1 mg |
| mAb anti-Human PSMA, YPSMA-1 | MO-T40086A | 0.1 mg |
| mAb anti-Human PSMA, YPSMA-2 | MO-T40086B | 0.1 mg |
| mAb anti-Human PSMA, 4H11 | MO-T40086C | 0.1 mg |
| mAb anti-Human PSMA, 7F3 | MO-T40086D | 0.1 mg |
| mAb anti-Human PTMA, 8H12 | MO-T40087A | 0.1 mg |
| mAb anti-Human PTMA, 9A10 | MO-T40087B | 0.1 mg |
| mAb anti-Human PTMA, 6A3 | MO-T40087C | 0.1 mg |
| mAb anti-Human PTMA, 4G2 | MO-T40087D | 0.1 mg |
| mAb anti-Human PTMA, 5A10 | MO-T40087E | 0.1 mg |
| mAb anti-Human PTMA, 6H7 | MO-T40087F | 0.1 mg |
| mAb anti-Human PTMA, 1F2, Capture | MO-T40087G | 0.1 mg |
| mAb anti-Human PTMA, 4C3 | MO-T40087H | 0.1 mg |
| mAb anti-Human PTMA, 4A7, Detector | MO-T40087I | 0.1 mg |
| mAb anti-Human S100A7 (psoriasin), 9A4 | MO-T40088A | 0.1 mg |
| mAb anti-Human S100A7 (psoriasin), 2E6 | MO-T40088B | 0.1 mg |
| mAb anti-Human S100A7 (psoriasin), 1A10 | MO-T40088C | 0.1 mg |
| mAb anti-Human S100A7 (psoriasin), 5C2 | MO-T40088D | 0.1 mg |
| mAb anti-Human S100A7 (psoriasin), 10H9 | MO-T40088E | 0.1 mg |
| mAb anti-Human S100A7 (psoriasin), 2A3 | MO-T40088F | 0.1 mg |
| mAb anti-Human S100A7 (psoriasin), 2E5 | MO-T40088G | 0.1 mg |
| mAb anti-Human S100A7 (psoriasin), 5H12 | MO-T40088H | 0.1 mg |
| mAb anti-Human S100A7 (psoriasin), 9C7 | MO-T40088I | 0.1 mg |
| mAb anti-Human S100A7 (psoriasin), 9D5 | MO-T40088J | 0.1 mg |
| mAb anti-Human S100A7 (psoriasin), 3E7 | MO-T40088K | 0.1 mg |
| Human PSA ELISA Kit | EL10005 | 96 wells |
| Human IL-8 ELISA Kit | EL10008 | 96 wells |
| Human MCAF / MCP-1 ELISA Kit | EL10009 | 96 wells |
| Human EGF ELISA Kit | EL10010 | 96 wells |
| Human LH ELISA Kit | EL10011 | 96 wells |
| Human TSH ELISA Kit | EL10012 | 96 wells |
| Neonatal TSH ELISA Kit | EL10012N | 96 wells |
| Ultra-Sensitive Human TSH ELISA Kit | EL10012U | 96 wells |
| Human FSH ELISA Kit | EL10013 | 96 wells |
| Human Prolactin ELISA Kit | EL10014 | 96 wells |
| Human SAA ELISA Kit | EL10015 | 96 wells |
| Human SAA ELISA Kit (2nd Generation) | EL10015L | 96 wells |
| Human MCP-3 ELISA Kit | EL10016 | 96 wells |
| Human TNF-α ELISA Kit | EL10019 | 96 wells |
| Human GM-CSF ELISA Kit | EL10020 | 96 wells |
| Human IL-16 ELISA Kit | EL10021 | 96 wells |
| High Sensitivity Human CRP ELISA Kit | EL10022hs | 96 wells |
| Human IL-6 ELISA Kit | EL10023 | 96 wells |
| Human IFN-γ ELISA Kit | EL10024 | 96 wells |
| Human IL-2 ELISA Kit | EL10025 | 96 wells |
| Human IL-4 ELISA Kit | EL10026 | 96 wells |
| Human IL-10 ELISA Kit | EL10027 | 96 wells |
| Human IL-1β ELISA Kit | EL10028 | 96 wells |
| Human TGF-β1 ELISA Kit | EL10029 | 96 wells |
| Human Growth Hormone (hGH) ELISA Kit/Hormone Elisa | EL10030 | 96 wells |
| High Sensitivity Human Growth Hormone (H-hGH) ELISA Kit | EL10030H | 96 wells |
| Human Chorionic Gonadotropin (hCG) ELISA Kit | EL10031 | 96 wells |
| Human IL-12 (P70) ELISA Kit | EL10032 | 96 wells |
| Human IL-2 sRα ELISA Kit | EL10033 | 96 wells |
| Human IL-6 sR ELISA Kit | EL10034 | 96 wells |
| Human IL-5 ELISA Kit | EL10035 | 96 wells |
| HAMA ELISA Kit | EL10036 | 96 wells |
| Human IL-13 Rα2 ELISA Kit | EL10039 | 96 wells |
| Human IL-1α ELISA Kit | EL10040 | 96 wells |
| Human IL-7 ELISA Kit | EL10041 | 96 wells |
| Human IL-11 ELISA Kit | EL10042 | 96 wells |
| Human IL-15 ELISA Kit | EL10044 | 96 wells |
| Human M-CSF ELISA Kit | EL10046 | 96 wells |
| Human TNF-β ELISA Kit | EL10047 | 96 wells |
| Human bFGF ELISA Kit | EL10048 | 96 wells |
| Human Alphafetoprotein (AFP) ELISA Kit | EL10049 | 96 wells |
| Human B2MG ELISA Kit | EL10051 | 96 wells |
| Human Carcinoembryonic Antigen (CEA) ELISA Kit | EL10052 | 96 wells |
| Human IL-17A ELISA Kit | EL10053 | 96 wells |
| Human IL-13 ELISA Kit | EL10054 | 96 wells |
| Human IL-22 ELISA Kit | EL10055 | 96 wells |
| Human IL-9 ELISA Kit | EL10056 | 96 wells |
| Human Amyloid Beta Peptide 42 ELISA Kit | EL10057 | 96 wells |
| Human Programmed Death-Ligand 1 (PD-L1) ELISA Kit | EL10058 | 96 wells |
| Human Programmed Death-1 (PD-1) ELISA Kit | EL10059 | 96 wells |
| Human IL-18 ELISA Kit | EL10060 | 96 wells |
| Multiplex Human Cytokine ELISA Kit (Inflammatory) | EM10001 | 96 wells |
| Multiplex Human Cytokine ELISA Kit (M1/M2/MDSC Cytokines) | EM10002 | 96 wells |
| Multiplex Human Cytokine ELISA Kit (Th1/Th2/Th17) | EM10003 | 96 wells |
| Mouse IL-17A ELISA Kit | MEC1001 | 96 wells |
| Mouse IFN-γ ELISA Kit | MEC1002 | 96 wells |
| Mouse TNF-α ELISA Kit | MEC1003 | 96 wells |
| Mouse GM-CSF ELISA Kit | MEC1004 | 96 wells |
| Mouse MCP-1 ELISA Kit | MEC1005 | 96 wells |
| Mouse IL-2 ELISA Kit | MEC1006 | 96 wells |
| Mouse IL-5 ELISA Kit | MEC1007 | 96 wells |
| Mouse IL-6 ELISA Kit | MEC1008 | 96 wells |
| Mouse IL-4 ELISA Kit | MEC1009 | 96 wells |
| Mouse IL-1β ELISA Kit | MEC1010 | 96 wells |
| Mouse IL-1α ELISA Kit | MEC1011 | 96 wells |
| Mouse TGF-β1 ELISA Kit | MEC1012 | 96 wells |
| pAb anti-Human CRP, Tracer (HRP Labeled) | AI20009P | 0.2 mL |
| mAb anti-Human TNF-α, CH8820, Capture | MO-C40003B | 0.1 mg |
| mAb anti-Human TNF-α, B1E4, Detector | MO-C40003E | 0.1 mg |
| mAb anti-Human TNF-α, B1E4, Tracer (HRP Labeled) | MO-C40003T | 0.2 mL |
| mAb anti-Human TNF-α, B1E4, Tracer (Biotin Labeled) | MO-C40003TB | 0.1 mL |
| mAb anti-Human IL-8, I8-S2, Capture | MO-C40017A | 0.1 mg |
| mAb anti-Human IL-8, I8-60, Detector | MO-C40017D | 0.1 mg |
| mAb anti-Human IL-8, I8-60, Tracer (HRP Labeled) | MO-C40017T | 0.2 mL |
| mAb anti-Human IL-8, I8-60, Tracer (Biotin Labeled) | MO-C40017TB | 0.1 mL |
| mAb anti-Human MCP-1, S14, Capture | MO-C40021B | 0.1 mg |
| mAb anti-Human MCP-1, S101, Detector | MO-C40021D | 0.1 mg |
| mAb anti-Human MCP-1, S101, Tracer (HRP Labeled) | MO-C40021T | 0.2 mL |
| mAb anti-Human MCP-1, S101, Tracer (Biotin Labeled) | MO-C40021TB | 0.1 mL |
| mAb anti-Human SAA, 115, Capture | MO-C40028A | 0.1 mg |
| mAb anti-Human SAA, 607, Detector | MO-C40028E | 0.1 mg |
| mAb anti-Human SAA, 607, Tracer (HRP Labeled), 0.2mL | MO-C40028T | 0.2 mL |
| mAb anti-Human SAA, 607, Tracer (Biotin Labeled), 0.1mL | MO-C40028TB | 0.1 mL |
| mAb anti-Human EGF, S-134, Capture | MO-C40044D | 0.1 mg |
| mAb anti-Human EGF, S-146, Detector | MO-C40044F | 0.1 mg |
| mAb anti-Human EGF, S-146, Tracer (HRP Labeled) | MO-C40044T | 0.2 mL |
| mAb anti-Human EGF, S-146, Tracer (Biotin Labeled) | MO-C40044TB | 0.1 mL |
| mAb anti-Human MCP-3, 113, Detector | MO-C40088A | 0.1 mg |
| mAb anti-Human MCP-3, 542, Capture | MO-C40088G | 0.1 mg |
| mAb anti-Human MCP-3, 113, Tracer (HRP Labeled) | MO-C40088T | 0.2 mL |
| mAb anti-Human MCP-3, 113, Tracer (Biotin Labeled) | MO-C40088TB | 0.1 mL |
| mAb anti-Human IL-16, 323, Detector | MO-C40089J | 0.1 mg |
| mAb anti-Human IL-16, 398, Capture | MO-C40089K | 0.1 mg |
| mAb anti-Human IL-16, 323, Tracer (HRP Labeled) | MO-C40089T | 0.2 mL |
| mAb anti-Human GM-CSF, 59, Capture | MO-C40090B | 0.1 mg |
| mAb anti-Human GM-CSF, 429, Detector | MO-C40090D | 0.1 mg |
| mAb anti-Human GM-CSF, 429, Tracer (HRP Labeled) | MO-C40090T | 0.2 mL |
| mAb anti-Human GM-CSF, 429, Tracer (Biotin Labeled) | MO-C40090TB | 0.1 mL |
| mAb anti Human IL-18 clone 2A10, Capture | MO-C40094A | 0.1mg |
| mAb anti Human IL-18 clone 10H4, Detector | MO-C40094B | 0.1mg |
| mAb anti human IL-18 clone 10H4, Tracer (Biotin Labeled) | MO-C40094TB | 0.1 mL |
| mAb anti Human IL-15 clone 5E8, Capture | MO-C40095A | 0.1mg |
| mAb anti Human IL-15 clone B1H6, Detector | MO-C40095B | 0.1mg |
| mAb anti human IL-15 clone B1H6, Tracer (Biotin labeled) | MO-C40095TB | 0.1 mL |
| mAb anti-HIV-1 P24 (Core Protein), 473, Detector | MO-I40002A | 0.1 mg |
| mAb anti-HIV-1 P24 (Core Protein), 340, Capture | MO-I40002D2 | 0.1 mg |
| mAb anti-HIV-1 P24 (Core Protein), 473, Tracer (HRP), 0.2 mL | MO-I40002T2 | 0.2 mL |
| mAb anti-Human PD-1 / CD279, 7G12, Tracer (Biotin labeled) | MO-L40043TB | 0.1 mL |
| mAb anti Human PD-L1 clone 12B4, Detector | MO-L40044I | 0.1 mg |
| mAb anti Human PD-L1 clone 15G3, Capture | MO-L40044N | 0.1 mg |
| mAb anti human PD-L1 clone 12B4, Tracer (Biotin Labeled) | MO-L40044TB | 0.1 mL |
| mAb anti-hGH, YC6, Capture | MO-M40012A | 0.1 mg |
| mAb anti-hGH, YC8, Tracer (HRP Labeled), 0.2 mL | MO-M40012T | 0.2 mL |
| mAb anti-hGH, YC8, Tracer (Biotin Labeled), 0.1 mL | MO-M40012TB | 0.1 mL |
| mAb anti-Human B2MG, D2E9, Capture | MO-M40021C | 0.1 mg |
| mAb anti-Human B2MG, D3A2, Detector | MO-M40021F | 0.1 mg |
| mAb anti-Human B2MG, D3A2, Tracer (HRP Labeled), 0.2mL | MO-M40021T | 0.2 mL |
| mAb anti-human CRP, 63F4, Capture | MO-M40023A | 0.1 mg |
| mAb anti-human TSH, TSH-2, Detector | MO-M40046A | 0.1 mg |
| mAb anti-human TSH, TSH-1, Capture | MO-M40046B | 0.1 mg |
| mAb anti-human TSH, TSH-2, Tracer (HRP Labeled), 0.2 mL | MO-M40046T | 0.2 mL |
| mAb anti-Human Prolactin, PRL-1, Capture | MO-M40047B | 0.5 mg |
| mAb anti-Human Prolactin, PRL-2, Tracer (HRP Labeled), 0.2 mL | MO-M40047T | 0.2 mL |
| mAb anti-Human LH, LH-1, Capture | MO-M40048B | 0.5 mg |
| mAb anti-Human LH, LH-2, Tracer (HRP Labeled), 0.2 mL | MO-M40048T | 0.2 mL |
| mAb anti-hCG, HCG-1, Capture | MO-M40049B | 0.5 mg |
| mAb anti-hCG, HCG-2, Tracer (HRP Labeled), 0.2 mL | MO-M40049T | 0.2 mL |
| mAb anti-Human FSH, FSH-1, Capture | MO-M40050B | 0.5 mg |
| mAb anti-Human FSH, FSH-2, Tracer (HRP Labeled) | MO-M40050T | 0.2 mL |
| mAb anti-Amyloid β Peptide 42, CA9 10C11, Detector | MO-M40093B | 0.5 mg |
| mAb anti-Amyloid β Peptide 42, CA9 10C11, Tracer (Biotin) | MO-M40093TB | 0.1 mL |
| mAb anti-Amyloid β Peptide N-terminal, NT 5B8, Capture | MO-M40094D | 0.5 mg |
| mAb anti-Amyloid β Peptide 40, CV9 7B10, Detector | MO-M40095A | 0.1 mg |
| mAb anti-Amyloid β Peptide 40, CV9 7B10, Tracer (Biotin) | MO-M40095TB | 0.1 mL |
| mAb anti-Human AFP, AFP-Y2, Detector | MO-T40007A | 0.1 mg |
| mAb anti-Human AFP, AFP-Y1, Capture | MO-T40007B | 0.1 mg |
| mAb anti-Human AFP, AFP-2, Tracer (HRP Labeled), 0.2 mL | MO-T40007T | 0.2 mL |
| mAb anti-Human CEA, CEA-Y2, Detector | MO-T40051A | 0.1 mg |
| mAb anti-Human CEA, CEA-Y1, Capture | MO-T40051B | 0.1 mg |
| mAb anti-Human CEA, CEA-Y2, Tracer (HRP Labeled), 0.2 mL | MO-T40051T | 0.2 mL |
| mAb anti-Human Free PSA, 103, Detector | MO-T40052A | 0.1 mg |
| mAb anti-Human Free PSA, 108, Capture | MO-T40052B | 0.1 mg |
| mAb anti-Human Free PSA, 103, Tracer (HRP Labeled), 0.2 mL | MO-T40052T | 0.2 mL |
| mAb anti-Human PSA, CHYH1, Capture | MO-T40081A | 0.1 mg |
| mAb anti-Human PSA, CHYH2, Dectector | MO-T40081B | 0.1 mg |
| mAb anti-Human PSA, CHYH2, Tracer (HRP Labeled), 0.2 mL | MO-T40081T | 0.2 mL |
| Human Chorionic Gonadotrophin (hCG), 10 mg | AP30002 | 10 mg |
| Human Immunoglobulin G (IgG), 10 mg | IG30001 | 10 mg |
| Mouse Immunoglobulin G (IgG), 10 mg | IG41002 | 10 mg |
| Mouse Immunoglobulin G2b (IgG2b), 10 mg | IG41004 | 10 mg |
| Rat Immunoglobulin G (IgG) | IG42003 | 10 mg |
| Human Umbilical Cord Serum, 10 mL | S30010 | 10 mL |
| ELISA Coating (EC) Stabilizer, 500 mL | S7001 | 500 mL |
| Human IL-8 Matched Antibody Pair for ELISpot | SL10008A | 5 × 96 wells |
| Human IL-8 Development Set for ELISpot | SL10008B | 5 × 96 wells |
| Human IL-8 ELISpot Kit | SL10008E | 6 X 96 wells |
| Human MCAF (MCP-1) Matched Antibody Pair for ELISpot | SL10009A | 5 × 96 wells |
| Human MCAF (MCP-1) Development Set for ELISpot | SL10009B | 5 × 96 wells |
| Human MCAF (MCP-1) ELISpot Kit | SL10009E | 6 X 96 wells |
| Human GM-CSF Matched Antibody Pair for ELISpot | SL10020A | 5 × 96 wells |
| Human GM-CSF Development Set for ELISpot | SL10020B | 5 × 96 wells |
| Human GM-CSF ELISpot Kit | SL10020E | 6 X 96 wells |
| Human IFN-γ Matched Antibody Pair for ELISpot | SL10024A | 5 × 96 wells |
| Human IFN-γ Development Set for ELISpot | SL10024B | 5 × 96 wells |
| Human IFN-γ ELISpot Kit | SL10024E | 6 X 96 wells |
| Human IL-12 (P70) ELISpot Kit | SL10032E | 6 X 96 wells |
| TMB Solution (500 mL Part A & 500 mL Part B) | SU6006 | 1.0 L |
| pAb Rabbit anti-HCV Virus, 1.0 mg | AI20006P | 1.0 mg |
| pAb Rabbit anti-HIV-1 p24, 1.0 mg | AI20008P | 1.0 mg |
| pAb anti-Human CRP, Tracer (HRP Labeled) | AI20009P | 0.2 mL |
| pAb Rabbit anti-Mouse IgG , 1.0 mg | AI50005 | 1.0 mg |
| pAb Rabbit anti-Mouse IgG - HRP Conjugated, 1.0 mL | AI50005P | 1.0 mL |
| pAb Rabbit anti-hGH, | AI50006P | 1.0 mg |
| pAb Chicken anti-human IL-8 (IgY fraction) | AI60001 | 1.0 mg |
| pAb Rabbit anti-Human FPRL-1 2nd Extracellular Loop | AI70001A | 0.1 mg |
| pAb Rabbit anti-Human FPRL-1 C-terminal | AI70001B | 0.1 mg |
| pAb Rabbit anti-Human PML [Ring Finger Domain] | AI70002A | 0.1 mg |
| pAb Rabbit anti-Human PML [B-box 1 domain] | AI70002B | 0.1 mg |
| pAb Rabbit anti-Bcl-2 | AI70003A | 0.1 mg |
| pAb Rabbit anti-Phospho-Bcl-2 (Thr56) | AI70003B | 0.1 mg |
| pAb Rabbit anti-Phospho-Bcl-xL (Thr115) | AI70003D | 0.1 mg |
| pAb Rabbit anti-Phospho c-kit (Tyr719) | AI70004A | 0.1 mg |
| pAb Rabbit anti-Phospho IKK-γ (Ser31) | AI70005A | 0.1 mg |
| pAb Rabbit anti-NF-κB-p65 (RelA) | AI70006A | 0.1 mg |
| pAb Rabbit anti-Phospho-NF-қB-p65 (Ser276) | AI70007A | 0.1 mg |
| pAb Rabbit anti-Phospho-NF-қB-p65 (Ser468) | AI70008A | 0.1 mg |
| pAb Rabbit anti-Phospho NF-қB-p105/p50 (Ser337) | AI70009A | 0.1 mg |
| pAb Rabbit anti-Human Serum Albumin (HSA) | AI80001 | 0.1 mg |
| pAb Rabbit anti-Human Fibrinogen, 0.1 mg | AI80002 | 0.1 mg |
| pAb Rabbit anti-Human Transferrin | AI80003 | 0.1 mg |
| pAb Rabbit anti-Human IgA, 0.5 mg | AI80004 | 0.5 mg |
| pAb Rabbit anti-human IgM, 0.5 mg | AI80005 | 0.5 mg |
| pAb Rabbit anti-Human TREK-1 (K2p2.1) | AI80006A | 0.1 mg |
| pAb Rabbit anti-Mouse Kchip1 | AI80007 | 0.1 mg |
| pAb Rabbit anti-Mouse Kchip4 | AI80008 | 0.1 mg |
| pAb Rabbit anti-Mouse Kv4.3 | AI80010A | 0.1 mg |
| pAb Rabbit anti-Mouse TRPV1 | AI80011A | 0.1 mg |
| pAb Rabbit anti-Mouse TRPV3 | AI80012A | 0.1 mg |
| pAb Rabbit anti-Human JAK2 | AI80013A | 0.1 mg |
| pAb Rabbit anti-Human Glutathione S Transferase (GST), 0.1 mg | AI80014 | 0.1 mg |
| pAb Rabbit anti-Human Amyloid beta peptide 42 | AI90001 | 0.1 mg |
| pAb Rabbit anti-Human Amyloid beta peptide 43 | AI90002 | 0.1 mg |

Cayman Chemical向全球科学工作者提供多研究领域的生化、免疫试剂和分析试剂盒,其产品被广泛应用于肿瘤、氧化氮、神经学、凋亡、氧化性损伤、内分泌学等不同研究领域。Cayman Chemical可提供用于检测的特色试剂盒,如:类花生酸类物质、游离的生物标志、环核苷、激素及氧化氮等;也提供多种高质量试剂,包括:类花生酸类物质、氧化氮试剂及许多相关脂质、脂肪酸、酶和抗体。"
Cayman Chemical Company is an American biotechnology company founded in 1980, headquartered in Ann Arbor, MI. The company provides chemicals that are used primarily by universities and pharmaceutical companies for research and the development of medicines. The company is also known as a provider of reference standards to state and federal crime labs for use in the detection of rapidly evolving designer drugs. Small quantities of these known reference standards are analyzed using mass spectrometry and gas chromatography techniques to match against forensic evidence, usually confiscated by law enforcement, or forensic toxicological evidence collected in the form of biological samples such as urine, blood, or tissue.
Cayman chemical的主要产品包括:
Chemical Analysis
Chemical Synthesis
Bioanalysis
Medicinal Chemistry
Prostaglandin APIs
R&D Services
Manufacturing
Biochemicals
Assay Kits
Antibodies
Proteins
Analytical Standards
Certified Reference Materials
" data-original="http://genvivo.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="Cayman Chemical"> Cayman Chemical地址:武汉市洪山区光谷大道35号光谷总部国际时代 二期1栋1301
电话:18771149750
传真:15172469628
邮箱:sales@amyjet.com
0.3578